Grant Number,Title,Funding Amount in USD,Start Year,End Year,Funder,Funder Country
30410203277,疫苗－整体方案,1208,2004,2004,National Natural Science Foundation of China,China
620792,Engineering Inhalable Vaccines,26956,2017,2018,Natural Sciences and Engineering Research Council,Canada
599115,Engineering Inhalable Vaccines,26403,2016,2017,Natural Sciences and Engineering Research Council,Canada
251564,HIV Vaccine research,442366,2003,2007,National Health and Medical Research Council,Australia
334174,HIV Vaccine Development,236067,2005,2009,National Health and Medical Research Council,Australia
910292,Dengue virus vaccine.,130890,1991,1993,National Health and Medical Research Council,Australia
578221,Engineering Inhalable Vaccines,27386,2015,2016,Natural Sciences and Engineering Research Council,Canada
IC18980360,Schistosomiasis Vaccine Network.,0,1998,2000,European Commission,Belgium
7621798,Pneumococcal Ribosomal Vaccines,46000,1977,1980,Directorate for Biological Sciences,United States
255890,Rational vaccine design,7138,2003,2004,Natural Sciences and Engineering Research Council,Canada
275254,Rational vaccine design,13447,2004,2005,Natural Sciences and Engineering Research Council,Canada
280679,Aquaticulture vaccines,23051,2004,2005,Natural Sciences and Engineering Research Council,Canada
295878,Aquaticulture vaccines,24761,2005,2006,Natural Sciences and Engineering Research Council,Canada
468513,Vaccines for aquaculture,4363,2010,2011,Natural Sciences and Engineering Research Council,Canada
Z01BC010456,Cancer Vaccine Development,0,2002,2002,National Cancer Institute,United States
R44AI033256,CRYPTOSPORIDIUM RECOMBINANT VACCINES,0,1992,1996,National Institute of Allergy and Infectious Diseases,United States
R43AI040514,ANTIRETROVIAL DNA VACCINE,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI036810,VACCINE FOR LEISHMANIASIS,0,1996,1996,National Institute of Allergy and Infectious Diseases,United States
N01CB021155,CANCER VACCINE PRODUCTION,0,1992,1993,National Cancer Institute,United States
N01CB021154,CANCER VACCINE PRODUCTION,0,1992,1993,National Cancer Institute,United States
N01CB021026,CANCER VACCINE PRODUCTION,0,1992,1993,National Cancer Institute,United States
N01BC021155,CANCER VACCINE PRODUCTION,0,1992,1996,National Cancer Institute,United States
N01BC021154,CANCER VACCINE PRODUCTION,0,1992,1993,National Cancer Institute,United States
N01BC021026,CANCER VACCINE PRODUCTION,0,1992,1996,National Cancer Institute,United States
N01AI095375,HIV VACCINE PRODUCTION,61313,1999,2006,National Institute of Allergy and Infectious Diseases,United States
N01AI015093,VACCINES FOR SAIDS,0,1990,1996,National Institute of Allergy and Infectious Diseases,United States
2813100406,Entwicklung viraler Vektorvakzinen/Markervakzinen,1136603,2006,2010,Federal Ministry of Food and Agriculture,Germany
2010-00636,Herpes Vaccine project,29617,2010,2011,VINNOVA,Sweden
R43AI030577,VACCINE DELIVERY SYSTEM FOR LIVE ROTAVIRUS VACCINES,0,1990,1991,National Institute of Allergy and Infectious Diseases,United States
F05TW003686,IMMUNOLOGICAL STUDIES IN VACCINES OF RABIES VACCINE,0,1986,1986,Fogarty International Center,United States
IRLX0703,Vaccine adjuvant commercialisation project,22635,2007,2008,"Ministry of Business, Innovation and Employment",New Zealand
SE1202,Shelf life of vaccines,67917,1990,1993,Department for Environment Food and Rural Affairs,United Kingdom
OD0302,Duck viral Hepatitis vaccine,6767,1992,1993,Department for Environment Food and Rural Affairs,United Kingdom
946099,Novel vaccines against AIDS,70976,1994,1995,National Health and Medical Research Council,Australia
980664,Synthetic peptides as vaccines,447769,1998,2002,National Health and Medical Research Council,Australia
145882,Klebsiella Vaccines and Immunotherapeutics,63197,2002,2004,National Health and Medical Research Council,Australia
943201,Malaria and Vaccine Research,1750550,1994,1998,National Health and Medical Research Council,Australia
930849,Vaccines for complex organisms,36032,1993,1993,National Health and Medical Research Council,Australia
N/A,DENGUE VACCINE DEVELOPMENT,50000,1985,1986,United States Department of the Army,United States
2196,Novel Vaccines for Measles,86356,2008,2010,Saskatchewan Health Research Foundation,Canada
79426,Streptococcal mastitis vaccine development,20686,1992,1993,Natural Sciences and Engineering Research Council,Canada
153466,Bovine adenovirus vectored vaccines,259061,1997,2000,Natural Sciences and Engineering Research Council,Canada
388654,Vaccine formulation and delivery,178772,2005,2009,Natural Sciences and Engineering Research Council,Canada
60520,Streptococcal mastitis vaccine development,38760,1993,1994,Natural Sciences and Engineering Research Council,Canada
519469,Vaccins thérapeutiques anti-cancer,4498,2012,2013,Natural Sciences and Engineering Research Council,Canada
464727,Subunit vaccines for aquaculture,31616,2010,2011,Natural Sciences and Engineering Research Council,Canada
366693,Pan-PRovincial Vaccine ENTerprise,3230548,2007,2008,Natural Sciences and Engineering Research Council,Canada
285269,Vaccine formulation and delivery,49951,2004,2005,Natural Sciences and Engineering Research Council,Canada
379652,Vaccines for farm fish,4184,2007,2008,Natural Sciences and Engineering Research Council,Canada
516321,Vaccins thérapeutiques anti-cancer,4498,2012,2013,Natural Sciences and Engineering Research Council,Canada
495065,Vaccins thérapeutiques anti-cancer,4546,2011,2012,Natural Sciences and Engineering Research Council,Canada
379651,Vaccines for farm fish,4184,2007,2008,Natural Sciences and Engineering Research Council,Canada
330169,Improving cancer vaccine efficacy,15247,2006,2007,Natural Sciences and Engineering Research Council,Canada
U01IP000464,NEW VACCINE SURVEILLANCE NETWORK,3455122,2011,2017,Centers for Disease Control and Prevention,United States
U01CA061398,MACROPHAGE-BASED MELANOMA VACCINE,0,1993,1997,National Cancer Institute,United States
R44AI034679,HELICOBACTER PYLORI MUCOSAL VACCINE,0,1993,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI040433,MALARIA VACCINE ADJUVANT DEVELOPMENT,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R21AI045391,HIV GP120 GLYCOCONJUGATE VACCINES,485633,2000,2004,National Institute of Allergy and Infectious Diseases,United States
N01AI065303,SIMIAN VACCINE EVALUATION UNITS,838646,1996,2001,National Institute of Allergy and Infectious Diseases,United States
N01AI052576,TESTING VACCINES IN CHILDREN,0,1985,1990,National Institute of Allergy and Infectious Diseases,United States
N01AI045240,HLA AND VACCINES (BAA),0,1994,1999,National Institute of Allergy and Infectious Diseases,United States
N01AI045211,AIDS VACCINE EVALUATION UNITS,52371,1994,2000,National Institute of Allergy and Infectious Diseases,United States
N01AI045210,AIDS VACCINE EVALUATION UNITS,113783,1994,2000,National Institute of Allergy and Infectious Diseases,United States
N01AI045209,AIDS VACCINE EVALUATION UNITS,378543,1994,2000,National Institute of Allergy and Infectious Diseases,United States
N01AI045208,AIDS VACCINE EVALUATION UNITS,113000,1994,2000,National Institute of Allergy and Infectious Diseases,United States
N01AI045207,AIDS VACCINE EVALUATION UNITS,534630,1994,2000,National Institute of Allergy and Infectious Diseases,United States
N01AI045206,AIDS VACCINE EVALUATION UNITS,39000,1994,2000,National Institute of Allergy and Infectious Diseases,United States
N01AI015114,EVALUATION OF CANDIDATE VACCINES,0,1991,1996,National Institute of Allergy and Infectious Diseases,United States
N01AI005065,AIDS VACCINE EVALUATION UNITS,0,1990,1995,National Institute of Allergy and Infectious Diseases,United States
H23IP000735,IMMUNIZATION & VACCINES FOR CHILDREN,8807296,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000689,Hepatatis B Vaccine Pilot,1265722,2012,2015,Centers for Disease Control and Prevention,United States
0311300 /8,Verbundprojekt: Verfahren zur Impfstoffentwicklung: Rekombinante Impfstoffe Impfstoffe gegen virale Erkrankungen von Salmoniden,183534,1996,1999,Federal Ministry of Education and Research,Germany
39789010,基因工程疫苗的机理,120798,1998,2000,National Natural Science Foundation of China,China
31210103063,坏死杆菌重组亚单位疫苗研究,1901,2012,2012,National Natural Science Foundation of China,China
30910303037,2009亚洲DNA疫苗国际年会,5854,2009,2009,National Natural Science Foundation of China,China
30410203257,2004年DNA疫苗国际会议,1691,2004,2004,National Natural Science Foundation of China,China
30010427,第三届疫苗研究年会,1086,2000,2000,National Natural Science Foundation of China,China
313170,BioChancePLUS: Therapeutische Vakzinierung gegen Multiple Sklerose,512009,2004,2007,Federal Ministry of Education and Research,Germany
BCTR9831,Improved Vaccines for Breast Cancer Immunotherapy,200000,1998,2001,Susan G. Komen Breast Cancer Foundation,United States
N/A,Sterilization Vaccine for Cattle,0,2006,2006,Council for International Exchange of Scholars,United States
N/A,Vaccine Production in Plants,0,2011,2011,Council for International Exchange of Scholars,United States
N/A,Novel vaccine formulations against tuberculosis,295003,2002,2005,Canadian Institutes of Health Research,Canada
UM1AI148373,Kaiser Washington VTEU supplement 20-0003,8621578,2019,2022,National Institute of Allergy and Infectious Diseases,United States
U54CA242639,"Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico",3462240,2019,2024,National Cancer Institute,United States
R21CA230878,Engaging practices and communities in the development of interventions to promote HPV vaccine uptake,202928,2019,2021,National Cancer Institute,United States
U54CA242977,Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center,3574360,2019,2024,National Cancer Institute,United States
R01AI147839,Understanding the rectal mucosal effects of cross-sex hormone therapy among US and Thai transgender women,1416359,2019,2024,National Institute of Allergy and Infectious Diseases,United States
R01CA240983,Targeting Neoantigens in Triple Negative Breast Cancer,1266874,2019,2024,National Cancer Institute,United States
K08HS026510,Improving Immunization Rates in Transplant Candidates Through the Use of a Health Information Technology Tool,297078,2019,2024,Agency for Healthcare Research and Quality,United States
R01CA235615,RCT to Evaluate an Implementation Strategy to Increase Optimal Use of HPV Vaccine in Primary Care,1132371,2019,2024,National Cancer Institute,United States
R21AI141822,Adapting Motivational Interviewing for Maternal Immunization (MI4MI),436589,2019,2021,National Institute of Allergy and Infectious Diseases,United States
R01AG064800,Cutaneous pathogen-specific tissue resident memory T cells in human aging,1276621,2019,2024,National Institute on Aging,United States
P01CA229143,Improving Uptake of Cervical Cancer Prevention Services in Appalachia,4819553,2019,2024,National Cancer Institute,United States
U01AI141919,PERSISTENCE OF PROTECTION CONFERRED BY SHINGRIX AGAINST HERPES ZOSTER IN OLDER ADULTS,1444740,2019,2024,National Institute of Allergy and Infectious Diseases,United States
U01AI141981,The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination,1221707,2019,2024,National Institute of Allergy and Infectious Diseases,United States
K01AI137123,Characterizing parental beliefs to support optimization of vaccine introduction,197368,2018,2023,National Institute of Allergy and Infectious Diseases,United States
R01AI141712,Eliminating human rabies: impact of enhanced vaccination coverage,1143705,2018,2023,National Institute of Allergy and Infectious Diseases,United States
R01HD093628,Evaluation of the Presumptively Initiating Vaccines and Optimizing Talk with Motivational Interviewing (PIVOT with MI) Intervention,1902392,2018,2023,National Institute of Child Health and Human Development,United States
R01CA229261,Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition,627949,2018,2024,National Cancer Institute,United States
R01HD096277,Group Antenatal Care to Promote a Healthy Pregnancy and Optimize Maternal and Newborn Outcomes:  A Cluster Randomized Controlled Trial,1137876,2018,2023,National Institute of Child Health and Human Development,United States
UG3HD096908,Developing and Testing a Multi-level Package of Interventions for an Integrated Care Delivery Model of HIV Prevention and Treatment Targeting Adolescent Girls in Zambia,2125858,2018,2020,National Institute of Child Health and Human Development,United States
R21CA222936,Improving Transition Readiness in Adolescent and Young Adult (AYA) Survivors of Childhood Cancer,376258,2018,2021,National Cancer Institute,United States
KL2TR002554,Institutional Career Development Core,4921290,2018,2023,National Center for Advancing Translational Sciences,United States
R01CA217889,"Less Pain, Less Fuss, Right Now! and Make It Count!- Multilevel Interventions for Patient, Parent, and Practice to Enhance Provider Recommendations for HPV Vaccination",1721894,2018,2023,National Cancer Institute,United States
R37CA226682,A Randomized Controlled Trial of an HPV Vaccine Intervention for Young Sexual Minority Men,1634563,2018,2022,National Cancer Institute,United States
R01AI132348,Transcriptomic Signatures of Influenza Vaccine Responses,2346427,2018,2022,National Institute of Allergy and Infectious Diseases,United States
R01AI135029,Improving Influenza Vaccination Delivery Across a Health System by the Electronic Health Records Patient Portal,2176605,2018,2022,National Institute of Allergy and Infectious Diseases,United States
R01AI129709,Non-inferiority study of adjuvanted vs. high dose flu vaccine in residents of long term care,3385066,2017,2020,National Institute of Allergy and Infectious Diseases,United States
UH3AG056925,Physical Resiliencies:  Indicators and Mechanisms in the Elderly Collaborative,1719272,2017,2022,National Institute on Aging,United States
P50CA206963,SPORE in Myeloid Malignancies,8505691,2017,2022,National Cancer Institute,United States
R03AG052778,Resistance Exercise to Improve Vaccine Outcomes in Older Adults,153000,2017,2020,National Institute on Aging,United States
R01HD089939,Microfluidic Assessment of Clinical Outcomes in Preterm Newborns,2707925,2017,2022,National Institute of Child Health and Human Development,United States
U01IP001073,Impact of AFIX and Physician-to-Physician Engagement on HPV Vaccination in Primary Care: An RCT,1499255,2017,2020,Centers for Disease Control and Prevention,United States
U01AI131310,Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1,4567862,2017,2022,National Institute of Allergy and Infectious Diseases,United States
U01AI131285,Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure,6204118,2017,2022,National Institute of Allergy and Infectious Diseases,United States
R01AI129715,Evaluating the relationship of CD101 and UBE2V1 to genital mucosal inflammation,2850090,2017,2022,National Institute of Allergy and Infectious Diseases,United States
R01AI131914,Identification of Novel Mucosal Immune Mechanisms Involved in Protection from HIV-1,3117491,2017,2022,National Institute of Allergy and Infectious Diseases,United States
U01AI129789,Controlled Infection Trial to Test Efficacy of Hookworm Vaccine with Different TLR Agonists,3136765,2017,2021,National Institute of Allergy and Infectious Diseases,United States
R01AI130398,Effects of aging on primary and secondary vaccine responses in a 15-year longitudinal cohort,3339739,2017,2022,National Institute of Allergy and Infectious Diseases,United States
U01AI131296,Therapeutic vaccination and PD-1 blockade in treated HIV disease,5933389,2017,2022,National Institute of Allergy and Infectious Diseases,United States
R01CA213130,Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial,3324968,2017,2022,National Cancer Institute,United States
R01CA202261,Improving HPV Vaccination Delivery in Pediatric Primary Care: The STOP-HPV Trial,2094641,2017,2023,National Cancer Institute,United States
R01CA207401,Increasing HPV vaccine uptake in community-based pediatric practices,2177346,2016,2021,National Cancer Institute,United States
R01HD086045,Flu2Text: A Multi-Site Study assessing an Intervention for 2nd Dose of Influenza Vaccine,2414954,2016,2020,National Institute of Child Health and Human Development,United States
R01DA038875,Non-Metabolized Pregnenolone Derivatives:New Treatment for Cannabis Use Disorder,3077623,2016,2020,National Institute on Drug Abuse,United States
U01IP001035,"Outpatient VE for seasonal flu, pandemic flu and RSV in a large, diverse network",7800000,2016,2021,Centers for Disease Control and Prevention,United States
P50CA196510,Washington University SPORE in Pancreatic Cancer,10948829,2016,2021,National Cancer Institute,United States
U01MD011281,A Pragmatic Trial of An Adaptive eHealth HIV Prevention Program for Diverse Adolescent MSM,9657789,2016,2021,National Institute on Minority Health and Health Disparities,United States
R01CA201429,Helping the poor quit smoking: specialized quitlines and meeting basic needs,2896141,2016,2021,National Cancer Institute,United States
R21CA208329,Using Text Messaging to Increase HPV Vaccination among Young Sexual Minority Men,381753,2016,2019,National Cancer Institute,United States
R01HL134211,Malaria chemoprevention in children with sickle cell anemia in Western Kenya,2867299,2016,2021,National Heart Lung and Blood Institute,United States
R01MH107297,PC4PrEP: Integrating PrEP into Primary Care,3601728,2016,2021,National Institute of Mental Health,United States
R01AG052495,Mindfulness based stress reduction for family caregivers of dementia patients,2814138,2016,2021,National Institute on Aging,United States
K01MH109871,Effects of inflammation on neural mechanisms of threat sensitivity in posttraumatic stress disorder,736508,2016,2021,National Institute of Mental Health,United States
U01HL130163,INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED),19063816,2016,2021,National Heart Lung and Blood Institute,United States
R21TW010262,mHealth-assisted conditional cash transfers to improve timeliness of vaccinations,353570,2016,2018,Fogarty International Center,United States
R21CA202011,"Maximizing HPV vaccination: Real-time Reminders, Guidance, and Recommendations",371547,2016,2020,National Cancer Institute,United States
R01AI118422,Perturbing the HIV Reservoir with Immune Stimulation,3818277,2016,2021,National Institute of Allergy and Infectious Diseases,United States
R01CA187219,Peptide vaccine immunotherapy for children with recurrent low-grade astrocytomas,1761886,2016,2020,National Cancer Institute,United States
R03EB015955,Enhancing Health Care Access with Cellular Technology,256339,2015,2018,National Institute of Biomedical Imaging and Bioengineering,United States
R21TW010252,Point-of-Delivery Prenatal Test Results through mHealth to Improve Birth Outcome,322369,2015,2018,Fogarty International Center,United States
R35CA197633,Immuno-Targeted Therapy for Melanoma,3979310,2015,2022,National Cancer Institute,United States
R01CA187707,State Immunization Information Systems to Improve HPV Vaccination Rates,2378680,2015,2020,National Cancer Institute,United States
R01CA175517,Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine),3086214,2015,2021,National Cancer Institute,United States
R01CA197296,Reprogramming the pancreatic tumor microenvironment with immunotherapy,2305214,2015,2021,National Cancer Institute,United States
R01HS023582,SINC: Synchronized Immunization Notifications,749875,2015,2019,Agency for Healthcare Research and Quality,United States
R21CA194831,Increasing HPV Vaccine Coverage among Young Adult Gay and Bisexual Men,382920,2015,2018,National Cancer Institute,United States
R01CA195563,Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade Gliomas,2836396,2015,2020,National Cancer Institute,United States
R01AI114903,Centralized IIS-Based Reminder-Recall to Increase Influenza Vaccination Rates,2811087,2015,2020,National Institute of Allergy and Infectious Diseases,United States
R21HD084115,SMS mobile technology to improve early childhood vaccine coverage in Guatemala,340715,2015,2019,National Institute of Child Health and Human Development,United States
R01AI110482,A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage,3956523,2014,2019,National Institute of Allergy and Infectious Diseases,United States
R01CA181045,CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection,3593996,2014,2020,National Cancer Institute,United States
R44CA183075,In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study,1689340,2014,2020,National Cancer Institute,United States
R01AG047922,ACTIVE IMMUNOTHERAPY FOR COGNITIVE DECLINE IN ADULTS WITH DOWN SYNDROME,1607948,2014,2019,National Institute on Aging,United States
R01CA187076,The role of the PI3K pathway in immune resistance,1980000,2014,2020,National Cancer Institute,United States
R21DA036407,Improving Identification of Social Harm among Substance Abusers in HIV Trials,405419,2014,2017,National Institute on Drug Abuse,United States
R21HD076216,"Spillover effects of water, sanitation, and hygiene interventions on child health",364537,2014,2017,National Institute of Child Health and Human Development,United States
U10CA180794,ECOG-ACRIN Network Group Statistics and Data Management Center,51333324,2014,2025,National Cancer Institute,United States
U10CA180820,ECOG-ACRIN Network Group Operations Center,87255624,2014,2025,National Cancer Institute,United States
U10CA180888,SWOG Network Group Operations Center of the NCTN,72999856,2014,2025,National Cancer Institute,United States
U10CA180868,NRG Oncology Network Group Operations Center,104891832,2014,2025,National Cancer Institute,United States
U10CA180830,NCI NCTN- Network Lead Academic Participating Site: USC,3023086,2014,2019,National Cancer Institute,United States
UM1CA186704,Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer,6775451,2014,2021,National Cancer Institute,United States
U19AI111825,Integrating innate and adaptive pathways in vaccine responses,18260314,2014,2024,National Institute of Allergy and Infectious Diseases,United States
R21AI110736,Simultaneous Immune Enhancement and Disruption of HIV-1 Latency by Poly ICLC,148064,2014,2016,National Institute of Allergy and Infectious Diseases,United States
K01AI106961,A Practice-Provider-Parent-Adolescent intervention to increase HPV vaccination,471220,2014,2019,National Institute of Allergy and Infectious Diseases,United States
R01AI108479,Mechanisms of Impaired HIV-associated B cell and Pneumococcal Vaccine responses,2288600,2013,2019,National Institute of Allergy and Infectious Diseases,United States
P50CA159981,RPCI-UPCI Ovarian Cancer SPORE,11641270,2013,2020,National Cancer Institute,United States
R01AG045973,Immune response to pneumococcal vaccination in aging HIV positive adults.,1514444,2013,2020,National Institute on Aging,United States
R01CA178414,Developing a self-persuasion intervention promoting adolescent HPV vaccination,2250510,2013,2019,National Cancer Institute,United States
R01CA178846,MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES,1184376,2013,2019,National Cancer Institute,United States
R01CA174858,Peptide vaccine-based immunotherapy for children with recurrent ependymomas.,945448,2013,2017,National Cancer Institute,United States
U01AI105872,Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV,5275178,2013,2019,National Institute of Allergy and Infectious Diseases,United States
R18HS021163,School Located Influenza Vaccinations for Children: Community-Wide Dissemination,952829,2012,2018,Agency for Healthcare Research and Quality,United States
UC4DK097835,NIDDK Type 1 Diabetes TrialNet Data Coordinating Center,45000000,2012,2017,National Institute of Diabetes and Digestive and Kidney Diseases,United States
R01AI099243,Assessing measures to eliminate transmission of cholera in Haiti,6805175,2012,2022,National Institute of Allergy and Infectious Diseases,United States
R42CA153845,Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma,2000000,2012,2020,National Cancer Institute,United States
R01CA169118,Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature,2070886,2012,2018,National Cancer Institute,United States
R01DA035145,Efficacy of Internet-based HIV prevention,3734615,2012,2018,National Institute on Drug Abuse,United States
U01HD071889,Antiviral prophylaxis to prevent perinatal transmission of HBV in Thailand,1980750,2012,2017,National Institute of Child Health and Human Development,United States
R01AI099601,Causes of rotavirus vaccine failure in Zambian children,643442,2012,2017,National Institute of Allergy and Infectious Diseases,United States
R01CA168719,Measles Virotherapy for Multiple Myeloma,1495557,2012,2015,National Cancer Institute,United States
R01CA166559,Quadrivalent Human Papillomavirus (HPV) Vaccine in Cancer Survivors,3020788,2012,2019,National Cancer Institute,United States
U19AI100266,The effect of peptide therapy and allergen provocation on Fel d1-specific T Cells,6510000,2012,2019,National Institute of Allergy and Infectious Diseases,United States
U01IP000475,Influenza Immunization of Children in India,3070024,2011,2016,Centers for Disease Control and Prevention,United States
U01IP000497,EMIT: Evaluating Modes of Influenza Transmission using a Human Challenge Model,10849395,2011,2014,Centers for Disease Control and Prevention,United States
P01HS021138,Center for Research in Implementation Science and Prevention (CRISP),4466826,2011,2015,Agency for Healthcare Research and Quality,United States
R01HD070821,"Integrated Brain, Body and Social Intervention for ADHD",4162049,2011,2016,National Institute of Child Health and Human Development,United States
K23AG040708,Vitamin D and Immunosenescence in Older Long-Term Care Residents,623572,2011,2015,National Institute on Aging,United States
R01CA158318,mTOR inhibition for generating memory T cells to enhance ovarian tumor immunity,1663124,2011,2019,National Cancer Institute,United States
U01IP000501,Immunization Delivery in Obstetrics and Gynecology Settings,1049974,2011,2015,Centers for Disease Control and Prevention,United States
U01GH000152,CONDUCTING PUBLIC HEALTH RESEARCH IN THAILAND BY THE MINISTRY OF PUBLIC HEALTH (MO,10590632,2011,2016,Centers for Disease Control and Prevention,United States
R01DA030296,"Couples-Based HIV/STI Prevention for Drug-Involved, African American MSM",2981836,2011,2018,National Institute on Drug Abuse,United States
U19AI096113,Martin Delaney Collaboratory to Eradicate HIV-1 Infection,39466444,2011,2017,National Institute of Allergy and Infectious Diseases,United States
R01GM097531,Novel Mechanisms and Approaches to Treat Neonatal Sepsis,2333507,2011,2020,National Institute of General Medical Sciences,United States
U01IP000310,Adolescent Vaccination in the Medical Home: Established and Innovative Strategies,887375,2010,2014,Centers for Disease Control and Prevention,United States
U19AT006028,Bastyr/UW Oncomycology Translational Research Center,4038890,2010,2015,National Center for Complementary and Integrative Health,United States
U01CA154967,Cancer Immunotherapy Trials Network Central Operations and Statistical Center,16826048,2010,2017,National Cancer Institute,United States
P50CA138293,Seattle Cancer Consortium Breast SPORE,10967142,2010,2017,National Cancer Institute,United States
U54CA153513,Asian Community Cancer Health Disparities Center (ACCHDC),5202041,2010,2017,National Cancer Institute,United States
D43CA153784,Zambian Cervical Cancer Research Capacity Initiative,1814038,2010,2015,National Cancer Institute,United States
U19AI090019,Vaccination and infection: indicators of immunological health and responsiveness,17337264,2010,2016,National Institute of Allergy and Infectious Diseases,United States
U19AI090023,System Biological Analyses of Innate and Adaptive Responses to Vaccination,41860480,2010,2022,National Institute of Allergy and Infectious Diseases,United States
R01CA143130,Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses,6391168,2010,2020,National Cancer Institute,United States
R01CA125244,Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas,2436181,2010,2016,National Cancer Institute,United States
U19AI089683,"The Intransigence of Malaria in Malawi: Understanding Hidden Reservoirs, Successful Vectors and Prevention Failures",16795696,2010,2024,National Institute of Allergy and Infectious Diseases,United States
R01AI081558,Immune Response to Pneumococcal Vaccination in HIV Infected Adults,1461020,2010,2014,National Institute of Allergy and Infectious Diseases,United States
R21HD061709,Metabolic and Immune Responses to Flu Vaccine in Mitochondrial Disease Patients,432419,2010,2012,National Institute of Child Health and Human Development,United States
R01CA140602,Vaccination with IL-15 DC to Generate Melanoma-specific Protective Memory T Cells,1410939,2010,2015,National Cancer Institute,United States
R18HS018158,Flu Alert: Influenza Vaccine Alerts for Providers in the Electronic Health Record,1200000,2009,2013,Agency for Healthcare Research and Quality,United States
U19AI084024,The UPMC Sexually Transmitted Infections Cooperative Research Center,12910007,2009,2017,National Institute of Allergy and Infectious Diseases,United States
RC1LM010513,Population versus Practice-Based Interventions to Increase Immunization Rates,999999,2009,2012,United States National Library of Medicine,United States
RC2HL101632,Viral/Immune parameters of Dengue and WNV in donors: blood safety implications,2118432,2009,2013,National Heart Lung and Blood Institute,United States
RC2DA028837,Phase III Study of a Nicotine Vaccine for Smoking Cessation,10007124,2009,2011,National Institute on Drug Abuse,United States
RC2CA148491,A Phase I Study of EGFRvIII Peptide Vaccination (CDX-110) after Conventional Radi,1548119,2009,2013,National Cancer Institute,United States
RC1AI086900,Translational Research: From Mechanisms of Influenza Transmission to Prevention,995688,2009,2012,National Institute of Allergy and Infectious Diseases,United States
K01TW008401,"Preliminary Effectiveness Analysis of Universal Rotavirus Immunization, Nicaragua",507037,2009,2013,Fogarty International Center,United States
P30AG034532,NBER Roybal Center for Behavior Change in Health,5297949,2009,2024,National Institute on Aging,United States
U01IP000320,Strategies to Vaccinate all Children for Influenza in a Practice Setting,780000,2009,2013,Centers for Disease Control and Prevention,United States
P50CA140158,Experimental Therapeutics of Leukemia,11230671,2009,2015,National Cancer Institute,United States
R01HL095163,Cigarette Smoke and Susceptibility to Influenza Infection,1993842,2009,2015,National Heart Lung and Blood Institute,United States
R21AG031470,The Effect of Fact versus Myth Messages on Receipt of Influenza Vaccination,250100,2009,2011,National Institute on Aging,United States
R21CA134813,Stress management and vaccine response among women at risk for breast cancer,425920,2009,2012,National Cancer Institute,United States
R21CA133859,A Bi-Institutional Pilot Study of Vaccinations for Patients with Low Grade Glioma,677685,2009,2012,National Cancer Institute,United States
R01AT004313,Meditation and Exercise for Prevention of Acute Respiratory Infection,1185662,2009,2012,National Center for Complementary and Integrative Health,United States
R01CA134633,Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells,3972426,2009,2022,National Cancer Institute,United States
P01CA132714,Directing Tumor-specific T cells to Tumors,6766119,2009,2016,National Cancer Institute,United States
R44HD056647,Relieving Pediatric Immunization Pain Using A Reusable Personal Device,1061888,2009,2012,National Institute of Child Health and Human Development,United States
R21CA130340,CD8+ T cell Activation and Infiltration Into Breast Tumors Following Vaccination,628726,2009,2012,National Cancer Institute,United States
P01TP000300,"TP08-001, PREPAREDNESS AND EMERGENCY RESPONSE CENTER",5206088,2008,2015,Office of Public Health Preparedness and Response,United States
P01AT005013,Metabolic and Immunologic Effects of Meditation,6759902,2008,2015,National Center for Complementary and Integrative Health,United States
R01HD060338,Effect of a sanitation & nutrition intervention on HIV-exposed infant health,2005228,2008,2014,National Institute of Child Health and Human Development,United States
R21CA132279,EBV-Specific T-Cell Therapy for Nasopharynx Cancer: Immunomodulation and Response,759710,2008,2012,National Cancer Institute,United States
R01DA025223,Multisite Controlled Trial of Cocaine Vaccine (1of 6) Lead Site/ Houston Treatmen,1677185,2008,2015,National Institute on Drug Abuse,United States
R21CA128232,Therapeutic HPV vaccination for stage IB1 cervical cancer,582462,2008,2012,National Cancer Institute,United States
R01CA135272,RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells,2349699,2008,2013,National Cancer Institute,United States
R01CA129517,Adoptive T Cell Therapy for the Treatment of HER2 Overexpressing Cancers,2236359,2008,2013,National Cancer Institute,United States
U18IP000184,"Annual Estimates of Influenza Vaccine Effectiveness:  Davidson County, TN",2950681,2008,2012,Centers for Disease Control and Prevention,United States
R21DA024388,Nicotine Vaccine &Nicotine Occupancy of Brain Nicotinic Receptors,351268,2008,2011,National Institute on Drug Abuse,United States
R21CA123864,Clinical Trial of DRibble Vaccine in NSCLC,653850,2008,2011,National Cancer Institute,United States
R01HL086488,Development of a P. vivax immunization and sporozoite challenge model for human,1237748,2008,2014,National Heart Lung and Blood Institute,United States
UL1RR025744,Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1,22403116,2008,2013,National Center for Advancing Translational Sciences,United States
UL1RR025777,UAB Center for Clinical and Translational Science (CCTS) UL1,22323402,2008,2013,National Center for Advancing Translational Sciences,United States
U01CA132194,Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01),1607939,2008,2014,National Cancer Institute,United States
R21DA023521,An Arts Intervention for Drug-Using Homeless Youth,423500,2008,2011,National Institute on Drug Abuse,United States
R21CA132891,Effect on IL-2R Antibody on Regulatory T-cells in Patients with Malignant Gliomas,464100,2008,2009,National Cancer Institute,United States
U01IP000127,"EFFICACY OF OSELTAMIVIR IN REDUCING DURATION OF ILLNESS, VIRAL SHEDDING &TRANSIS",1428220,2007,2011,Centers for Disease Control and Prevention,United States
U01IP000129,Evaluation of vaccination reminder/recall systems for adolescent patients,95343,2007,2010,Centers for Disease Control and Prevention,United States
U54MD002316,Leveraging Bio-Cultural Mechanisms to Maximize the Impact of Multi-Level Preventable Disease Interventions with Southwest Populations,5652227,2007,2022,National Institute on Minority Health and Health Disparities,United States
P50DE019032,Spore in Head and Neck Cancer,27095948,2007,2019,National Institute of Dental and Craniofacial Research,United States
UL1RR024982,North and Central Texas Clinical and Translational Science Initiative (UL1),27945448,2007,2012,National Center for Advancing Translational Sciences,United States
UL1RR025008,Atlanta Clinical and Translational Science Institute (UL1),28984820,2007,2012,National Center for Advancing Translational Sciences,United States
R21AI077102,Impact of Bilateral Priming on Response to Unilateral Flu Vaccination,461300,2007,2011,National Institute of Allergy and Infectious Diseases,United States
K23NR010408,The Psychoneuroimmunology of Insomnia: Response to a Vaccine Challenge,420334,2007,2010,National Institute of Nursing Research,United States
R01AI075603,Diagnostic yield of induced sputum for rapid diagnosis of pulmonary tuberculosis,409744,2007,2013,National Institute of Allergy and Infectious Diseases,United States
U44AI069674,Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus,1299084,2007,2019,National Institute of Allergy and Infectious Diseases,United States
R01FD003369,PHASE 1 STUDY OF SAFETY &IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN,633556,2007,2012,United States Food and Drug Administration,United States
R01AI070018,Immune Reconstitution of HIV-1 Infected Zambian Children Initiating Antiretrovira,1813712,2007,2013,National Institute of Allergy and Infectious Diseases,United States
R21AI066957,"Immunity of neoantigen response in HCV, HIV, and HCV-HIV",426544,2007,2010,National Institute of Allergy and Infectious Diseases,United States
R21CA117152,Vaccination With Peptide-loaded alphaDC1s For Malignant Gliomas,564300,2007,2009,National Cancer Institute,United States
P30AI073961,Miami Center for AIDS Research,20620192,2006,2022,National Institute of Allergy and Infectious Diseases,United States
UL1RR024128,Duke CTSI,48090796,2006,2012,National Center for Advancing Translational Sciences,United States
UL1RR024160,The University of Rochester Clinical and Translational Science Institute,38732064,2006,2012,National Center for Advancing Translational Sciences,United States
U01CI000435,Pittsburgh Influenza Prevention Project,,2006,2009,Centers for Disease Control and Prevention,United States
U01CI000446,Evaluation of Masks as a Source Control NPI,,2006,2009,Centers for Disease Control and Prevention,United States
R01CA125614,Virotherapy for Relapsed Refractory Multiple Myeloma,1240272,2006,2012,National Cancer Institute,United States
U01IP000074,PiiiTCH Study,,2006,2008,Centers for Disease Control and Prevention,United States
R21AT002708,Synbiotics as Adjuvant to Influenza Vaccine in Elderly,356582,2006,2009,National Center for Complementary and Integrative Health,United States
R21CA123876,Therapeutic DNA-MVA prime boost vaccination for HPV disease,435650,2006,2010,National Cancer Institute,United States
U01CA121947,AIDS Malignancy Clinical Trials Consortium (AMC),54677484,2006,2015,National Cancer Institute,United States
P50CA121973,SPORE in Skin Cancer,22894338,2006,2019,National Cancer Institute,United States
UM1AI068614,LOC:  HIV Vaccine Trials Network,319524416,2006,2020,National Institute of Allergy and Infectious Diseases,United States
U01AI068632,International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group,109700264,2006,2013,National Institute of Allergy and Infectious Diseases,United States
U01AI068614,Leadership Group for a Global HIV Vaccine Clinical Trials Network,181539904,2006,2013,National Institute of Allergy and Infectious Diseases,United States
R01CA112358,Dendritic Cell Vaccine Targeting Melanoma-Associated Antigens in Malignant Glioma,1275311,2006,2012,National Cancer Institute,United States
R44CA121612,New Cancer Vaccine Technology Based on DRibbles Produced by Tumor Cells,3375529,2006,2016,National Cancer Institute,United States
R21AI069363,BLyS and IFN responses to antigen challenge in human SLE,417735,2006,2010,National Institute of Allergy and Infectious Diseases,United States
R01NR010004,HIV Testing and Women's Attitudes on HIV Vaccine Trials,2184669,2006,2012,National Institute of Nursing Research,United States
UM1CA121947,AIDS Malignancy Consortium (AMC),99538896,2006,2020,National Cancer Institute,United States
R01AI066992,Induction of HIV-specific Immune Responses,2691533,2006,2012,National Institute of Allergy and Infectious Diseases,United States
R01DP000339,Mechanisms &Therapeutic Effects of Relaxation Response,1446000,2005,2010,Centers for Disease Control and Prevention,United States
U01AI065683,Genetic diversity and protective immunity to malaria infection and disease,2964305,2005,2016,National Institute of Allergy and Infectious Diseases,United States
U19AI065683,Malaria Vaccine Trials in Mali,4748457,2005,2010,National Institute of Allergy and Infectious Diseases,United States
R01DA017894,Efficacy of a Nicotine Vaccine for Smoking Cessation,4010628,2005,2007,National Institute on Drug Abuse,United States
R01ES013611,Diesel-Induced Alterations of Influenza infectivity,3694722,2005,2017,National Institute of Environmental Health Sciences,United States
R21CA115043,GM - CSF - producing tumor cell line as a CML vaccine,653914,2005,2007,National Cancer Institute,United States
R21CA105837,Multimodality Therapy for Metastatic Breast Cancer,569924,2005,2008,National Cancer Institute,United States
R01MH072556,The STIRR Intervention for Dually Diagnosed Clients,1696698,2005,2010,National Institute of Mental Health,United States
R01CA112198,"Melanoma Vaccines with Peptides, Protein and Adjuvant",1579638,2005,2011,National Cancer Institute,United States
U01AI064002,Chemoprophylaxis for HIV Prevention in  Men,41279316,2004,2013,National Institute of Allergy and Infectious Diseases,United States
U01AI063565,CMV Subunit Vaccine in Young Women at Risk,4674628,2004,2012,National Institute of Allergy and Infectious Diseases,United States
P01AI057127,Immunopathogenesis of acute and early HIV infection,8985629,2004,2010,National Institute of Allergy and Infectious Diseases,United States
P50CA108786,SPORE in Brain Cancer,12266496,2004,2010,National Cancer Institute,United States
P30AI060354,Harvard University Center for AIDS Research,60230920,2004,2024,National Institute of Allergy and Infectious Diseases,United States
R21CA091624,Autologous Dendritic Cell Vaccines in NSCLC,603827,2004,2007,National Cancer Institute,United States
R21CA099265,Peptide Booster Vaccination in A2+ Melanoma Patients,583430,2004,2007,National Cancer Institute,United States
U01CI000164,A School-Based Intervention to Reduce Lyme Disease,,2004,2009,Centers for Disease Control and Prevention,United States
R01DE015324,MAGE-A3/HPV 16 Peptide Vaccines for Head and Neck Cancer,792436,2004,2010,National Institute of Dental and Craniofacial Research,United States
R43AI058870,iMIC for HIV Research,99941,2004,2005,National Institute of Allergy and Infectious Diseases,United States
P50CA098252,SPORE in Cervical Cancer,37810968,2003,2024,National Cancer Institute,United States
R01DA017476,A Randomized Trial of Vaccine Adherence in Young IDU,2010333,2003,2008,National Institute on Drug Abuse,United States
R01DA017482,HIV Vaccine Trials in Women,1653241,2003,2007,National Institute on Drug Abuse,United States
U54HD061221,Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional),14223792,2003,2024,National Institute of Child Health and Human Development,United States
U54RR019453,Rare Diseases CRC- Urea Cycle Disorders,7038501,2003,2009,National Center for Advancing Translational Sciences,United States
P50CA101451,Michigan Center for Health Communications Research II,18207004,2003,2015,National Cancer Institute,United States
R21CA105776,CTLA-4 Blockade in GM-CSF Vaccinated Patients,729356,2003,2006,National Cancer Institute,United States
P50CA101942,DF/HCC Kidney Cancer SPORE,35617792,2003,2020,National Cancer Institute,United States
R21CA105696,A Phase I/II Trial of a Therapeutic HPV Vaccine,606000,2003,2007,National Cancer Institute,United States
U19AI055794,Dendritic Cell-Based Immunotherapy for HIV Infection,1626362,2003,2013,National Institute of Allergy and Infectious Diseases,United States
U10HL074424,COPD Clinical Research Network - Data Coordinating Center,20977188,2003,2015,National Heart Lung and Blood Institute,United States
U54AI057168,Middle Atlantic Regional Center for Excellence for Biodefense and Emerging Infect,91450944,2003,2015,National Institute of Allergy and Infectious Diseases,United States
U54AI057159,New England Regional Center of Excellence in Biodefense and Emerging Infectious D,113703600,2003,2015,National Institute of Allergy and Infectious Diseases,United States
U19AI057229,"Influenza responses and repertoire in vaccination, infection and tonsil organoids.",63578120,2003,2024,National Institute of Allergy and Infectious Diseases,United States
U19AI057266,Vaccine Induced Immunity in the Young and Aged,58817920,2003,2024,National Institute of Allergy and Infectious Diseases,United States
P01AI055793,Basic and Clinical Studies of CpG ODN in HIV Disease,2201316,2003,2006,National Institute of Allergy and Infectious Diseases,United States
R01AI051355,PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE,865817,2003,2010,National Institute of Allergy and Infectious Diseases,United States
R01AI051986,HIV Therapy &Interruption RCT in Resource Poor Clinic,983015,2003,2007,National Institute of Allergy and Infectious Diseases,United States
K23CA100691,T Cell Memory After Immunization with a HER2 DNA Vaccine,655290,2003,2009,National Cancer Institute,United States
P01AG020677,"Aging Well, Sleeping Efficiently",17511796,2003,2017,National Institute on Aging,United States
P50CA105632,Reducing Cervical Cancer in Appalachia,17226688,2003,2017,National Cancer Institute,United States
R01DA014502,SYRINGE EXCHANGE BASED HEPATITIS B VACCINATION OF IDU'S,1607768,2003,2007,National Institute on Drug Abuse,United States
U01AI053719,INDO-US Collaboration to Develop Rotavirus Vaccines,1130283,2003,2008,National Institute of Allergy and Infectious Diseases,United States
U19AI053217,CIPRA-SA:  Safeguard the household: comprehensive AIDS research: Extension,44850708,2002,2012,National Institute of Allergy and Infectious Diseases,United States
U01DE014961,Integrated Microfluidic System for Oral Diagnostics,4200000,2002,2008,National Institute of Dental and Craniofacial Research,United States
R01HL072705,Cardiovascular Status of HAART-Exposed Infants/Children,5630880,2002,2009,National Heart Lung and Blood Institute,United States
P50CA096888,SPORE in Lymphoma,13583458,2002,2010,National Cancer Institute,United States
R01MH065867,SOUTH AFRICAN ADOLESCENT HEALTH PROMOTION PROJECT,5616071,2002,2011,National Institute of Mental Health,United States
P50CA097186,The Pacific Northwest Prostate Cancer SPORE,40271988,2002,2023,National Cancer Institute,United States
R01AI049644,Interventions to Increase HBV Vaccination in STD Clinics,2997512,2002,2008,National Institute of Allergy and Infectious Diseases,United States
R01CA093714,Chemotherapy plus vaccine for metastatic breast cancer,1769241,2002,2008,National Cancer Institute,United States
M01RR016587,GENERAL CLINICAL RESEARCH CENTER,6761860,2002,2007,National Center for Advancing Translational Sciences,United States
P30CA093373,Cancer Center Support Grant P30,59376908,2002,2021,National Cancer Institute,United States
K08AI051223,Cytokine-Augmented DNA Vaccine-Elicited Immunity to HIV,447620,2002,2005,National Institute of Allergy and Infectious Diseases,United States
R01MH064882,RCT OF STEPPING STONES BEHAVIOURAL INTERVENTION FOR HIV,1458000,2002,2007,National Institute of Mental Health,United States
R01CA095648,Immunotherapy for Renal Cell Carcinoma,2261484,2002,2012,National Cancer Institute,United States
R01AI051181,Hiv Immune Reactivity 'in Vivo' and 'In Vitro',2108792,2002,2008,National Institute of Allergy and Infectious Diseases,United States
P01CA095426,Innate Immunity: Elucidation and Modulation for Cancer Therapy,29634280,2002,2017,National Cancer Institute,United States
P01CA094237,ENHANCING T CELL THERAPY OF CANCER,27835980,2001,2020,National Cancer Institute,United States
R01AI050467,Role of Immunization Site in Eliciting Mucosal Immunity,1248486,2001,2004,National Institute of Allergy and Infectious Diseases,United States
U01HL069294,BMT Clinical Research Network Data Coordinating Center,63255056,2001,2011,National Heart Lung and Blood Institute,United States
U01DK061055,Type 1 Diabetes Trialnet: Operations Coord. Center,93180848,2001,2010,National Institute of Diabetes and Digestive and Kidney Diseases,United States
R01HL069114,Chlamydia Infection as a Risk Factor for Cerebrovascula*,1422870,2001,2006,National Heart Lung and Blood Institute,United States
R21CA094523,Immunotherapy with TRICOM Modified Dendritic Cells,634872,2001,2003,National Cancer Institute,United States
P01AI049364,"DNA/MWA Immunogens, Cross-clade Immune Responses",12774926,2001,2007,National Institute of Allergy and Infectious Diseases,United States
T32HD040672,Training in Epidemiology and Clinical Trials (TECT),4168854,2001,2017,National Institute of Child Health and Human Development,United States
U10HD040498,MULTICENTER NETWORK OF NEONATAL INTENSIVE CARE UNITS,2074426,2001,2007,National Institute of Child Health and Human Development,United States
U10HD040521,MULTICENTER NETWORK OF NEONATAL INTENSIVE CARE UNITS,2292384,2001,2009,National Institute of Child Health and Human Development,United States
U10HD040492,Eunice Kennedy Shriver NICHD Cooperative Multicenter Neonatal Research Network,5423450,2001,2016,National Institute of Child Health and Human Development,United States
U10HD040689,NICHD Cooperative Multicenter Neonatal Research Network,5631441,2001,2016,National Institute of Child Health and Human Development,United States
R01CA089102,IMMUNOTHERAPY WITH RENAL TUMOR RNA TRANSFECTED  CELLS,1032504,2001,2005,National Cancer Institute,United States
R01CA088972,CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA,1465467,2001,2006,National Cancer Institute,United States
U01AI058935,Protecutive immunity to human cholera in Bangladesh,7806005,2000,2016,National Institute of Allergy and Infectious Diseases,United States
P01AI047490,NOVEL HIV VACCINES,5698191,2000,2007,National Institute of Allergy and Infectious Diseases,United States
R01AG018367,BEHAVIORAL INTERVENTION FOR HERPES ZOSTER RISK IN AGING,1316250,2000,2005,National Institute on Aging,United States
R01AI045407,DISSEMINATED TUBERCULOSIS IN HIV INFECTION,4588139,2000,2005,National Institute of Allergy and Infectious Diseases,United States
U01AI045407,Disseminated Tuberculosis in HIV Infection,4287054,2000,2008,National Institute of Allergy and Infectious Diseases,United States
R01CA088058,ALLOGENIC PANCREATIC TUMOR VACCINE CELL LINE,1599665,2000,2005,National Cancer Institute,United States
R01AG016634,RANDOMIZED TRIAL OF TAPWATER TREATMENT IN THE ELDERLY,2858456,2000,2007,National Institute on Aging,United States
R01AI047062,Assessing Laboratory Correlates of Immune Protection,3606069,2000,2008,National Institute of Allergy and Infectious Diseases,United States
P50CA083639,The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer,33020950,1999,2017,National Cancer Institute,United States
U10CA081851,Comprehensive Cancer Center of Wake Forest COOP Research Base,22009600,1999,2015,National Cancer Institute,United States
R21CA082614,IMMUNE RESPONSE TO THE MUTATED GP?00 PEPTIDE (209O-2M),139348,1999,2001,National Cancer Institute,United States
R01CA082661,PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII,603043,1999,2006,National Cancer Institute,United States
P30CA082103,Cancer Center Support Grant,150120496,1999,2023,National Cancer Institute,United States
P01CA078673,"Immunotherapy with High Frequency, CEA Specific T Cells",13164640,1999,2010,National Cancer Institute,United States
P01AI045142,DEVELOPMENT OF A NOVEL MULTIENVELOPE AIDS VACCINE,7044139,1999,2006,National Institute of Allergy and Infectious Diseases,United States
R01AI044628,IN VIVO INDUCTION OF HIV SPECIFIC CTL BY DENDRITIC CELLS,2337090,1999,2004,National Institute of Allergy and Infectious Diseases,United States
P01AI043664,ANTIGEN DELIVERY FOR ADJUVANT HIV IMMUNOTHERAPY,3127447,1998,2006,National Institute of Allergy and Infectious Diseases,United States
N01AI085346,Malaria:Clinical Research and Trial Preparation Sites-26685346,2765994,1998,2003,National Institute of Allergy and Infectious Diseases,United States
U01HD036790,Data Ctr for the Cooperative Neonatal Research Network,21844932,1998,2008,National Institute of Child Health and Human Development,United States
U01CA076576,Phase I Trials of Anti-Cancer Agents,9098593,1998,2015,National Cancer Institute,United States
R01CA077544,Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine,5568224,1998,2018,National Cancer Institute,United States
P30CA076292,Moffitt Cancer Center Support Grant,63066708,1998,2022,National Cancer Institute,United States
P01CA073743,Dendritic Cell Biology and Therapy,12298725,1998,2011,National Cancer Institute,United States
K12CA076930,Career Development in Pediatric and Medical Oncology,9763326,1997,2021,National Cancer Institute,United States
R01AI041050,Control of Epidemic Influenza,4457497,1997,2009,National Institute of Allergy and Infectious Diseases,United States
U01AI041534,Understanding and Altering the Virologic Setpoint,10131316,1997,2008,National Institute of Allergy and Infectious Diseases,United States
P51OD011106,Wisconsin National Primate Research Center Support,89781568,1997,2022,Office of the Director,United States
P30CA072720,Cancer Center Support Grant,64367452,1997,2024,National Cancer Institute,United States
P50HL056384,Immune Dysregulation in Allergic Asthma,9745710,1996,2007,National Heart Lung and Blood Institute,United States
U10HD034216,Cooperative Multicenter Neonatal Research Network - UAB,6447199,1996,2016,National Institute of Child Health and Human Development,United States
P01CA068484,Therapeutic Index of Acute Lymphoblastic Leukemia,31949828,1995,2013,National Cancer Institute,United States
U01CA069853,Phase I Clinical Trials of Anti-Cancer Agents,3611323,1995,2009,National Cancer Institute,United States
U01CA069912,Phase I Clinical Trials of Anticancer Agents,10132902,1995,2014,National Cancer Institute,United States
U01CA062490,Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis,10220664,1994,2014,National Cancer Institute,United States
U01CA062461,Phase I Studies of Targeted Anti-Cancer Therapies,7240486,1994,2015,National Cancer Institute,United States
U01CA062500,EARLY CLINICAL TRIALS OF ANTIANGIOGENESIS AGENTS,,1994,1998,National Cancer Institute,United States
R01HL051630,EXPRESSION OF TUBERCULOSIS IN THE LUNG,2217527,1993,2007,National Heart Lung and Blood Institute,United States
U01CA061498,SYSTEMIC IMMUNITY BY PARTICLE MEDIATED BRM GENE TRANSFER,,1993,2001,National Cancer Institute,United States
P30CA060553,The Robert H. Lurie Comprehensive Cancer Center,107854592,1993,2023,National Cancer Institute,United States
P50CA058204,SPORE in Prostate Cancer,21273374,1992,2010,National Cancer Institute,United States
P50CA058223,SPORE in Breast Cancer,43018240,1992,2023,National Cancer Institute,United States
M01RR007122,General Clinical Research Center,35231168,1992,2011,National Center for Advancing Translational Sciences,United States
U01CA058211,TREATMENT OF NEUROBLASTOMA WITH IL2 TRANSDUCED TUMOR,,1992,1996,National Cancer Institute,United States
R01CA057653,Melanoma vaccines using MHC-associated peptides,3388834,1992,2014,National Cancer Institute,United States
R01AI032391,Killer Cells &Viral Load in Vertical HIV Infection,2711141,1991,2010,National Institute of Allergy and Infectious Diseases,United States
P30CA054174,Cancer Therapy & Research Center at UTHSCSA,40827196,1991,2020,National Cancer Institute,United States
R01AI030904,Protective CMI mechanisms of a dual-subtype FIV vaccine,4213791,1991,2015,National Institute of Allergy and Infectious Diseases,United States
U10HD021385,Cooperative Multicenter Network of Neontal Intensive Care Units,8748209,1991,2016,National Institute of Child Health and Human Development,United States
U10HD021397,Maternal Lifestyle Study,6688404,1991,2007,National Institute of Child Health and Human Development,United States
U10HD027880,NICHD Cooperative Multicenter Neonatal Research Network,6142607,1991,2016,National Institute of Child Health and Human Development,United States
U10HD027851,Eunice Kennedy Shriver NICHD Cooperative Multicenter Neonatal Research Network,5024081,1991,2016,National Institute of Child Health and Human Development,United States
P30CA051008,Georgetown University Lombardi Comprehensive Cancer Center Support Grant,54687552,1990,2023,National Cancer Institute,United States
R37CA051323,Natural History of HPV Infection to Neoplasia,15443312,1990,2017,National Cancer Institute,United States
P30CA044579,University of Virginia Cancer Center Support Grant,52850196,1987,2022,National Cancer Institute,United States
P30CA043703,Case Comprehensive Cancer Center Support Grant,101426208,1987,2023,National Cancer Institute,United States
K12HD000850,Pediatric Scientist Development Program (K12) 2017-2022,34799756,1986,2022,National Institute of Child Health and Human Development,United States
P01AG005842,Improving Health Outcomes for an Aging Population,39924648,1986,2023,National Institute on Aging,United States
P30CA036727,Fred & Pamela Buffett Cancer Center Support Grant,35622972,1984,2021,National Cancer Institute,United States
P50NS020023,SRC on Primary Tumors of the CNS,17310368,1984,2015,National Institute of Neurological Disorders and Stroke,United States
U10CA031946,Cancer and Leukemia Group B,158397808,1982,2015,National Cancer Institute,United States
U10CA032102,Southwest Oncology Group Treatment Grant,141286976,1981,2015,National Cancer Institute,United States
P01CA030206,Hematopoietic Cell Transplantation for Hematologic Malignancies,31844534,1981,2013,National Cancer Institute,United States
P30CA033572,Cancer Center Support Grant,55374368,1981,2022,National Cancer Institute,United States
U10CA027469,Gynecologic Oncology Group,132577192,1980,2015,National Cancer Institute,United States
P30CA014089,USC Norris Comprehensive Cancer Center (Core) Grant,132882592,1980,2020,National Cancer Institute,United States
P30CA015083,Mayo Comprehensive Cancer Center Grant,110102400,1980,2024,National Cancer Institute,United States
P30CA006927,Comprehensive Cancer Center Program at Fox Chase,124246648,1979,2021,National Cancer Institute,United States
P30CA022453,Cancer Center Support Grant,48334076,1979,2020,National Cancer Institute,United States
M01RR000070,General Clinical Research Center,32397614,1978,2008,National Center for Advancing Translational Sciences,United States
M01RR000032,General Clinical Research Center,23574104,1978,2008,National Center for Advancing Translational Sciences,United States
M01RR000633,GENERAL CLINICAL RESEARCH CENTER,20980404,1978,2007,National Center for Advancing Translational Sciences,United States
P30CA023074,University of Arizona Cancer Center - Cancer Center Support Grant,81123232,1978,2021,National Cancer Institute,United States
P01CA023766,Immunobiology of Allogeneic Hematopoietic Cell Transplantation,51138044,1978,2024,National Cancer Institute,United States
P30CA016672,Cancer Center Support Grant,207129520,1978,2024,National Cancer Institute,United States
P30CA023108,Cancer Center Support Grant,67678440,1978,2024,National Cancer Institute,United States
P30CA016056,Roswell Park Cancer Center Support Grant,83418016,1978,2024,National Cancer Institute,United States
U10CA021115,Eastern Cooperative Oncology Group Operations Office,132636432,1978,2016,National Cancer Institute,United States
P30CA006973,Regional Oncology Research Center,151138480,1978,2022,National Cancer Institute,United States
M01RR000042,General Clinical Research Center,40798736,1977,2007,National Center for Advancing Translational Sciences,United States
P30CA006516,Dana-Farber/Harvard Cancer Center,238734720,1977,2021,National Cancer Institute,United States
P30CA016042,Cancer Center Support Grant,94728944,1977,2025,National Cancer Institute,United States
P30CA021765,Cancer Center Support Grant (CCSG),117691216,1977,2024,National Cancer Institute,United States
P30CA016058,Cancer Center Support Grant,90288128,1977,2020,National Cancer Institute,United States
P30CA013330,Core Support for Cancer Center,82920984,1977,2022,National Cancer Institute,United States
P30CA014599,Cancer Center Support Grant,89704640,1977,2023,National Cancer Institute,United States
P30CA008748,Cancer Center Support Grant,250916048,1977,2023,National Cancer Institute,United States
P30CA015704,Cancer Center Support Grant,216676224,1977,2024,National Cancer Institute,United States
P01CA015396,Bone  Marrow Transplantation in Human Disease,38146988,1976,2019,National Cancer Institute,United States
P30CA014236,Cancer Center Support Grant,130248544,1976,2024,National Cancer Institute,United States
P30CA012197,Cancer Center Support Grant,38103464,1976,2022,National Cancer Institute,United States
P01HL009011,A RESEARCH AND RESOURCE PROGRAM IN BLOOD,,1976,1986,National Heart Lung and Blood Institute,United States
P30CA014520,UW Comprehensive CANCER CENTER SUPPORT,103526592,1976,2023,National Cancer Institute,United States
M01RR000030,GENERAL CLINICAL RESEARCH CENTER,20045440,1975,2006,National Center for Advancing Translational Sciences,United States
M01RR000039,GENERAL CLINICAL RESEARCH CENTER,21262572,1974,2007,National Center for Advancing Translational Sciences,United States
M01RR000044,General Clinical Research Center,13806891,1974,2006,National Center for Advancing Translational Sciences,United States
N/A,Development of recombinant TB vaccine,101459,1999,2003,Canadian Institutes of Health Research,Canada
N/A,Hepatitis C: Vaccines and Immunotherapy,9841,2000,2001,Canadian Institutes of Health Research,Canada
N/A,DNA vaccine for chlamydia,67329,1999,2001,Canadian Institutes of Health Research,Canada
211347,nd,1514,2016,2017,Fonds de Recherche du Québec – Nature et technologies,Canada
VIRX0201,New Generation Recombinant Viral Vaccine Vectors,81841,2002,2003,"Ministry of Business, Innovation and Employment",New Zealand
SWSS0402,The automated synthesis of tuberculosis vaccines,182350,2004,2007,"Ministry of Business, Innovation and Employment",New Zealand
2010-0029242,신변종 인플루엔자 바이러스 제어 연구,0,2010,2011,National Research Foundation of Korea,South Korea
762208,Mucosal Vaccine against HIV-1 Infection,66584,2008,2010,University Grants Committee,China
AF/090/97,Oral DNA Vaccines,638466,1997,1999,Innovation and Technology Commission,China
N/A,Microcontainers for oral vaccine delivery,579532,2014,2014,Danish Agency for Science and Higher Education,Denmark
N/A,Microcontainers for oral vaccine delivery,88992,2014,2014,Danish Agency for Science and Higher Education,Denmark
VM0108,EC collaborative study for tetanus vaccines,23691,1992,1993,Department for Environment Food and Rural Affairs,United Kingdom
SE2805,Antigenic properties of vaccine virus strains,230794,1996,1999,Department for Environment Food and Rural Affairs,United Kingdom
SE1203,Alternative methods of formulating FMDV vaccines,74889,1990,1993,Department for Environment Food and Rural Affairs,United Kingdom
SE1201,To maintain the footandmouth vaccine bank,552165,1990,1993,Department for Environment Food and Rural Affairs,United Kingdom
609967,Vaccins et adjuvants pour la vache laitière,3391,2016,2017,Natural Sciences and Engineering Research Council,Canada
606399,Prototype vaccine against sea lice,3391,2016,2017,Natural Sciences and Engineering Research Council,Canada
604388,Thermal Stabilization of Phage and Vaccines,3391,2016,2017,Natural Sciences and Engineering Research Council,Canada
159106,A DNA Vaccine to Prevent Schistosomiasis,71382,2001,2004,National Health and Medical Research Council,Australia
890745,Immune response to malaria vaccine candidate,229287,1989,1991,National Health and Medical Research Council,Australia
900006,Development of a contraceptive vaccine,46740,1990,1991,National Health and Medical Research Council,Australia
920969,Challenging the malaria vaccine development strategy,78134,1992,1998,National Health and Medical Research Council,Australia
596899,Diabetes Vaccine Development Centre (DVDC),5147415,2010,2017,National Health and Medical Research Council,Australia
900655,Vivax malaria sporozoite vaccine development,84188,1990,1992,National Health and Medical Research Council,Australia
920275,New vaccines produced by genetic engineering,136593,1992,1994,National Health and Medical Research Council,Australia
997640,A Mucosal HIV Polytype Vaccine,33003,1999,2001,National Health and Medical Research Council,Australia
960338,HIV (AIDS) vaccine delivery vectors,120675,1996,1998,National Health and Medical Research Council,Australia
920330,A vaccine for cervical cancer,133297,1992,1994,National Health and Medical Research Council,Australia
910123,Development of an oral pneumococcal vaccine.,68538,1991,1993,National Health and Medical Research Council,Australia
910471,Development of new types of vaccines.,116900,1991,1993,National Health and Medical Research Council,Australia
209187,DNA and avipox vaccines for HIV.,64693,2002,2007,National Health and Medical Research Council,Australia
456152,Characterisation of Neisseria meningitidis vaccine candidates,298213,2007,2013,National Health and Medical Research Council,Australia
950876,Towards a vaccine against hepatitis e,96548,1995,1997,National Health and Medical Research Council,Australia
880246,A modern vaccine against leptospirosis,158968,1988,1990,National Health and Medical Research Council,Australia
900820,Development of an improved pneumococcal vaccine,148678,1990,1992,National Health and Medical Research Council,Australia
971030,Additional vaccine antigens for chlamydia,109364,1997,1999,National Health and Medical Research Council,Australia
OPP3431,To support the Vaccine Leadership Conference,40000,2000,2001,Bill & Melinda Gates Foundation,United States
X46120----570027,風診生ワクチンに関する研究,5523,1971,1971,Japan Society for the Promotion of Science,Japan
X45120-----70027,風疹生ワクチンに関する研究,5523,1970,1970,Japan Society for the Promotion of Science,Japan
X44120----371029,流行性耳下腺炎生ワクチンに関する研究,6907,1969,1969,Japan Society for the Promotion of Science,Japan
X41120-----71094,インフルエンザ生ワクチンに関する研究,6907,1966,1966,Japan Society for the Promotion of Science,Japan
X00120----187045,インフルエンザ生ワクチンに関する研究,8978,1976,1976,Japan Society for the Promotion of Science,Japan
X00120----287054,インフルエンザ生ワクチンに関する研究,11050,1977,1977,Japan Society for the Promotion of Science,Japan
61771809,合成マラリアワクチンの開発研究,6907,1986,1986,Japan Society for the Promotion of Science,Japan
E 50,Biochemical characterization of a vaccine,0,2000,2002,FWF Austrian Science Fund,Austria
56770791,単純ヘルペスウイルスワクチンの研究,6559,1981,1981,Japan Society for the Promotion of Science,Japan
56870047,パラインフルエンザウイルスワクチンの開発,12430,1981,1981,Japan Society for the Promotion of Science,Japan
16922177,新規腫瘍ワクチンの作製,6934,2004,2004,Japan Society for the Promotion of Science,Japan
583834,Anti-Vaccine Blog Annotation Project,3518,2015,2016,Natural Sciences and Engineering Research Council,Canada
hrc_aae0a049,Vaccine-based immunotherapy of cancer,3578777,2010,2015,Health Research Council of New Zealand,New Zealand
N01AI95367-0-0-0,HIV VACCINE PRODUCTION,126906,1999,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI60019-4-0-1,Therapeutics/Vaccine Teams,5519281,2008,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI50040-5-0-1,Tularemia Vaccine Development,0,2005,2010,National Institute of Allergy and Infectious Diseases,United States
Y2080775,幽门螺杆菌磷酸钙纳米疫苗的研究,0,2008,2013,Science and Technology Department of Zhejiang Province,China
DRT-S98-93,Anti-tick Vaccines,50929,1999,2001,UC Discovery Grants (formerly IUCRP),United States
189030,SEVAPLANT - Secure Vaccine Production in Plants,8860,2008,2008,The Research Council of Norway,Norway
561325,Development of Novel Vaccines through Glycoengineering,4071,2014,2015,Natural Sciences and Engineering Research Council,Canada
BIO4980503,Mucosal vaccines against autoimmune disease,0,1998,2000,European Commission,Belgium
TS1*0347,DEVELOPMENT OF MALARIA VACCINE,0,1985,1987,European Commission,Belgium
TS2*0103,VACCINES AGAINST TROPICAL THEILERIOSIS,0,1989,1993,European Commission,Belgium
540031,Creation of an anti-diarrhea vaccine,4364,2013,2014,Natural Sciences and Engineering Research Council,Canada
8026742,Fish Biologics Symposium: Serodiagnostics and Vaccines,6536,1981,1981,Directorate for Engineering,United States
217170,Oral delievery of vaccines to salmonids,19106,2002,2003,Natural Sciences and Engineering Research Council,Canada
304464,Tumor associated carbohydrates and vaccine design,96926,2003,2006,Natural Sciences and Engineering Research Council,Canada
10244,Vaccines for bovine respiratory disease,10998,1996,1997,Natural Sciences and Engineering Research Council,Canada
42673,Vaccines for bovine respiratory disease,21960,1994,1995,Natural Sciences and Engineering Research Council,Canada
153531,Développement_d'un vaccin contre Streptococcus suis,64288,1999,2000,Natural Sciences and Engineering Research Council,Canada
134249,Development of subunit Streptococcus suis vaccines,45902,1997,1999,Natural Sciences and Engineering Research Council,Canada
29549,Development of subunit Streptococcus suis vaccines,23952,1995,1996,Natural Sciences and Engineering Research Council,Canada
137414,Développement_dun vaccin contre Streptococcus suis,66739,1998,1999,Natural Sciences and Engineering Research Council,Canada
454883,Carbohydrate-based anti cancer vaccines,193054,2006,2011,Natural Sciences and Engineering Research Council,Canada
511553,Vaccines comprising heat-sensitive transgenes,4998,2012,2013,Natural Sciences and Engineering Research Council,Canada
309395,A vaccine to inhibit tick feeding,79436,2004,2006,Natural Sciences and Engineering Research Council,Canada
175434,Porcine cicovirus pathogenesis and vaccine development,105178,1998,2001,Natural Sciences and Engineering Research Council,Canada
408200,DNA vaccine for avian influenza,4216,2008,2009,Natural Sciences and Engineering Research Council,Canada
240059,Oral delivery of vaccines and immunomodulators,72085,2000,2004,Natural Sciences and Engineering Research Council,Canada
421077,Bioinformatics and intelligent vaccine design,102599,2005,2010,Natural Sciences and Engineering Research Council,Canada
192792,Tumor Associated Carbohydrates and Vaccine design,52765,2000,2002,Natural Sciences and Engineering Research Council,Canada
410332,Developing plant based vaccines from forages,4216,2008,2009,Natural Sciences and Engineering Research Council,Canada
294165,Bovine adenovirus-3 vectored vaccines,580948,2003,2006,Natural Sciences and Engineering Research Council,Canada
372295,Possible peptide vaccine candidtates for leishmania,16102,2007,2008,Natural Sciences and Engineering Research Council,Canada
404453,Recombinant vaccine development for tenacibaculum maritimum,4216,2008,2009,Natural Sciences and Engineering Research Council,Canada
255717,Oral delievery of vaccines to salmonids,1634,2003,2004,Natural Sciences and Engineering Research Council,Canada
U13FD003568,Annual Conference on Vaccine Research,15000,2008,2013,United States Food and Drug Administration,United States
U01IP000019,Varicella and Viral Vaccine Preventable Disease,752462,2004,2011,Centers for Disease Control and Prevention,United States
U01AI056438,Alphavirus Replicon Vaccines to Encephalitis Viruses,7497149,2003,2009,National Institute of Allergy and Infectious Diseases,United States
U01AI037546,MALARIA VACCINE RESEARCH AND DEVELOPMENT PROJECT,0,1994,1996,National Institute of Allergy and Infectious Diseases,United States
U01AI030238,STRATEGIES FOR HIV VACCINE DEVELOPMENT,0,1990,1996,National Institute of Allergy and Infectious Diseases,United States
U01AI024762,LIPOSOME MICROENCAPSULATION OF VACCINE ANTIGENS,0,1987,1990,National Institute of Allergy and Infectious Diseases,United States
R56AI064745,MULTIVALENT VACCINE FOR LYMPHATIC FILARIASIS,310000,2006,2007,National Institute of Allergy and Infectious Diseases,United States
R56AI052012,An Envelope Containing HIV Pseudovirion Vaccine,247200,2002,2008,National Institute of Allergy and Infectious Diseases,United States
R55DC004583,MICROBIAL POPULATION STRATEGY FOR VACCINE DEVELOPMENT,100000,2001,2003,National Institute on Deafness and Other Communication Disorders,United States
R43CA069969,THERAPEUTIC TUMOR VACCINE AGAINST MUC-1,0,1996,1996,National Cancer Institute,United States
R43CA069967,SYNTHESIS OF RNA CANCER VACCINES,0,1996,1997,National Cancer Institute,United States
R43CA068957,DEVELOPMENT OF SYNTHETIC CANCER VACCINES,0,1996,1997,National Cancer Institute,United States
R43AI039909,NOVEL VACCINE FOR HELICOBACTER PYLORI,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI039894,HIV-1 VACCINE FOR DEVELOPING COUNTRIES,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI039346,DEVELOPMENT OF CAMPYLOBACTER FLAGELLIN SUBUNIT VACCINE,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI039324,DEVELOPMENT OF A NOVEL VACCINE STRATEGY,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI037354,SUSTAINED RELEASE FOR VACCINES AND ADJUVANTS,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI037352,BIODEGRADABLE MINERAL MICROSPHERE ADJUVANTS FOR VACCINES,0,1996,1998,National Institute of Allergy and Infectious Diseases,United States
R43AI024371,SYNTHETIC VACCINES UTILIZING BACULOVIRUS POLYHEDRA,0,1987,1987,National Institute of Allergy and Infectious Diseases,United States
R41AI040449,DEVELOPMENT OF ROTAVIRUS DNA VACCINES,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R41AI038606,BIVALENT CONJUGATED RSV PNEUMOCOCCUS VACCINE,0,1995,1997,National Institute of Allergy and Infectious Diseases,United States
R41AI036585,AVIRULENT SALMONELLA HOST-VECTOR VACCINE SYSTEMS,0,1994,1996,National Institute of Allergy and Infectious Diseases,United States
R29AI032463,SALMONELLA/HUMAN IMMUNODEFICIENCY VIRUS VACCINE VECTOR,0,1992,1997,National Institute of Allergy and Infectious Diseases,United States
R21DK057122,A VACCINE FOR IMMUNE MEDIATED DIABETES,160465,1999,2002,National Institute of Diabetes and Digestive and Kidney Diseases,United States
R21CA082869,CHIMERIC HER-2 PEPTIDE VACCINE,130785,1999,2002,National Cancer Institute,United States
R21AI046259,CYTOMEGALOVIRUS VECTORS FOR HIV VACCINE DEVELOPMENT,239250,1999,2002,National Institute of Allergy and Infectious Diseases,United States
R03DE011313,A RECOMBINANT PORPHYROMONAS GINGIVALIS VACCINE,0,1995,1997,National Institute of Dental and Craniofacial Research,United States
R03AI031994,INDO-US VACCINE ACTION PROGRAM,0,1991,1993,National Institute of Allergy and Infectious Diseases,United States
R03AI030994,INDO-US VACCINE ACTION PROGRAM,0,1990,1994,National Institute of Allergy and Infectious Diseases,United States
R03AI030346,INDO-US VACCINE ACTION PROGRAM,0,1990,1993,National Institute of Allergy and Infectious Diseases,United States
R03AI030345,INDO-US VACCINE ACTION PROGRAM,0,1990,1993,National Institute of Allergy and Infectious Diseases,United States
R03AI030344,INDO-US VACCINE ACTION PROGRAM,0,1990,1993,National Institute of Allergy and Infectious Diseases,United States
R01DE006153,CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITY,0,1982,2003,National Institute of Dental and Craniofacial Research,United States
R01CA085868,ENHANCING TUMOR VACCINE IMMUNOGENICITY BY ANTIGAL,409875,1999,2002,National Cancer Institute,United States
R01CA058484,IMMUNOLOGICAL EFFECTS OF MELANOMA VACCINE THERAPY,0,1993,1997,National Cancer Institute,United States
R01CA057820,BREAST TUMOR SPECIFIC IMMUNITY--VACCINE DESIGN,0,1992,1998,National Cancer Institute,United States
R01CA057778,ANTITUMOR ARTIFICIAL RECEPTORS AS CANCER VACCINES,0,1992,1997,National Cancer Institute,United States
R01AI046164,IMMUNOLOGICALLY FOCUSED APPROACH TO AIDS VACCINE,858983,1999,2004,National Institute of Allergy and Infectious Diseases,United States
R01AI037256,VACCINE INTERVENTION FOR LYME BORRELIOSIS,1709592,1994,2004,National Institute of Allergy and Infectious Diseases,United States
R01AI035027,SECOND-GENERATION VACCINES AGAINST LYME DISEASE,0,1993,1998,National Institute of Allergy and Infectious Diseases,United States
R01AI033544,MICROSPHERES TO ENHANCE VACCINE IMMUNOGENICITY,0,1992,1998,National Institute of Allergy and Infectious Diseases,United States
R01AI031064,RATIONALE FOR SPOROZOITE MALARIA VACCINE DEVELOPMENT,0,1992,1997,National Institute of Allergy and Infectious Diseases,United States
R01AI023269,NONLIVING VACCINE AGAINST S MANSONI,0,1986,1991,National Institute of Allergy and Infectious Diseases,United States
N43CM057766,MONOCLONAL ANTIBODY ANTI-IDIOTYPE TUMOR VACCINES,0,1985,1985,National Cancer Institute,United States
N43AI095018,ADENOVIRUS RECOMBINANTS FOR VACCINE EFFICACY,0,1989,1989,National Institute of Allergy and Infectious Diseases,United States
N43AI052603,DEVELOP LIVE ATTENUATED CYTOMEGALOVIRUS VACCINES,0,1985,1985,National Institute of Allergy and Infectious Diseases,United States
N01DE012430,INVESTIGATION OF ANTICARIES VACCINE IN PRIMATES,0,1981,1986,National Institute of Dental and Craniofacial Research,United States
N01CP050529,MODELS FOR AIDS VACCINE RESEARCH,0,1994,1998,National Cancer Institute,United States
N01BC050529,MODELS FOR AIDS VACCINE RESEARCH,0,1994,1998,National Cancer Institute,United States
N01AO082722,OPERATE EXPERIMENTAL VIRUS VACCINE LABORATORY,740515,1997,2002,National Institute of Allergy and Infectious Diseases,United States
N01AO052710,MFG OF YEAST-PRODUCED MALARIA VACCINES,0,1995,1999,National Institute of Allergy and Infectious Diseases,United States
N01AO015095,"INFECTIOUS AGENTS, VACCINES &ANTIMICROBIALS IN HUMANS",0,1990,1996,National Institute of Allergy and Infectious Diseases,United States
N01AI082681,EXPERIMENTAL VIRUS VACCINE PRODUCTION LABORATORY,0,1987,1992,National Institute of Allergy and Infectious Diseases,United States
N01AI052593,EFFICACY TRIAL OF COLD-ADAPTED VACCINES,0,1985,1991,National Institute of Allergy and Infectious Diseases,United States
N01AI052577,TESTING VACCINES IN ADOLESCENTS AND ADULTS,0,1985,1990,National Institute of Allergy and Infectious Diseases,United States
N01AI045204,HIV VACCINE TRIALS AND EPIDEMIOLOGY REPOSITORY,229246,1994,1999,National Institute of Allergy and Infectious Diseases,United States
N01AI042534,DEVELOP A VACCINE FOR GONORRHEA,0,1983,1985,National Institute of Allergy and Infectious Diseases,United States
N01AI032518,DEVELOP AN ACELLULAR BORDETELLA PERTUSSIS VACCINE,0,1983,1986,National Institute of Allergy and Infectious Diseases,United States
N01AI025137,INVESTIGATIONAL NEW DRUGS AND VACCINES,0,1992,1995,National Institute of Allergy and Infectious Diseases,United States
N01AI015130,ADVERSE REACTIONS OF CHILDHOOD VACCINES,0,1991,1994,National Institute of Allergy and Infectious Diseases,United States
N01AI005421,MALARIA VACCINE PRODUCTION &SUPPORT SERVICES,6077974,2000,2007,National Institute of Allergy and Infectious Diseases,United States
N01AI002639,CLINICAL EVALUATION OF LIVE HERPESVIRUS VACCINE,0,1979,1985,National Institute of Allergy and Infectious Diseases,United States
K04AI001087,ACELLULAR VACCINES AGAINST BACTERIAL PATHOGENS,0,1992,1997,National Institute of Allergy and Infectious Diseases,United States
H23IP922549,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,12176449,2003,2012,Centers for Disease Control and Prevention,United States
H23IP922545,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,28595532,2003,2012,Centers for Disease Control and Prevention,United States
H23IP922535,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,4359668,2003,2012,Centers for Disease Control and Prevention,United States
H23IP922533,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,3559620,2003,2012,Centers for Disease Control and Prevention,United States
H23IP922518,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,12787854,2003,2012,Centers for Disease Control and Prevention,United States
H23IP922507,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,132483632,2003,2012,Centers for Disease Control and Prevention,United States
H23IP922505,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,4848248,2003,2012,Centers for Disease Control and Prevention,United States
H23IP922504,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,2354105,2003,2012,Centers for Disease Control and Prevention,United States
H23IP922503,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,1027633,2003,2012,Centers for Disease Control and Prevention,United States
H23IP922502,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,3370321,2003,2012,Centers for Disease Control and Prevention,United States
H23IP822564,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,22485676,2003,2012,Centers for Disease Control and Prevention,United States
H23IP822560,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,5545506,2003,2012,Centers for Disease Control and Prevention,United States
H23IP822552,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,6238876,2003,2012,Centers for Disease Control and Prevention,United States
H23IP822546,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,4581647,2003,2012,Centers for Disease Control and Prevention,United States
H23IP822520,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,13332202,2003,2012,Centers for Disease Control and Prevention,United States
H23IP822510,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,5265499,2003,2012,Centers for Disease Control and Prevention,United States
H23IP722562,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,9078858,2003,2012,Centers for Disease Control and Prevention,United States
H23IP722543,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,19171620,2003,2012,Centers for Disease Control and Prevention,United States
H23IP722542,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,13750234,2003,2012,Centers for Disease Control and Prevention,United States
H23IP722509,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,12782071,2003,2012,Centers for Disease Control and Prevention,United States
H23IP622571,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,84654136,2003,2012,Centers for Disease Control and Prevention,United States
H23IP622566,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,9773650,2003,2012,Centers for Disease Control and Prevention,United States
H23IP622541,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,18633488,2003,2012,Centers for Disease Control and Prevention,United States
H23IP622532,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,11954660,2003,2012,Centers for Disease Control and Prevention,United States
H23IP622523,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,13452676,2003,2012,Centers for Disease Control and Prevention,United States
H23IP622512,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,9133450,2003,2012,Centers for Disease Control and Prevention,United States
H23IP522568,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,27272696,2003,2012,Centers for Disease Control and Prevention,United States
H23IP522565,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,19894560,2003,2012,Centers for Disease Control and Prevention,United States
H23IP522563,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,20886180,2003,2012,Centers for Disease Control and Prevention,United States
H23IP522556,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,36897780,2003,2012,Centers for Disease Control and Prevention,United States
H23IP522551,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,23057106,2003,2012,Centers for Disease Control and Prevention,United States
H23IP522537,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,30695332,2003,2012,Centers for Disease Control and Prevention,United States
H23IP522522,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,14725251,2003,2012,Centers for Disease Control and Prevention,United States
H23IP422554,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,32415946,2003,2012,Centers for Disease Control and Prevention,United States
H23IP422544,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,20465260,2003,2012,Centers for Disease Control and Prevention,United States
H23IP422536,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,18486918,2003,2012,Centers for Disease Control and Prevention,United States
H23IP422528,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,16958976,2003,2012,Centers for Disease Control and Prevention,United States
H23IP422527,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,14506256,2003,2012,Centers for Disease Control and Prevention,United States
H23IP422524,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,13074784,2003,2012,Centers for Disease Control and Prevention,United States
H23IP422521,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,35935876,2003,2012,Centers for Disease Control and Prevention,United States
H23IP422511,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,58067576,2003,2012,Centers for Disease Control and Prevention,United States
H23IP322572,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,7377398,2003,2012,Centers for Disease Control and Prevention,United States
H23IP322570,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,19605318,2003,2012,Centers for Disease Control and Prevention,United States
H23IP322567,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,6612114,2003,2012,Centers for Disease Control and Prevention,United States
H23IP322561,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,6472027,2003,2012,Centers for Disease Control and Prevention,United States
H23IP322559,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,36378536,2003,2012,Centers for Disease Control and Prevention,United States
H23IP322538,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,11256214,2003,2012,Centers for Disease Control and Prevention,United States
H23IP322519,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,22522020,2003,2012,Centers for Disease Control and Prevention,United States
H23IP222576,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,25629016,2003,2012,Centers for Disease Control and Prevention,United States
H23IP222575,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,51502832,2003,2012,Centers for Disease Control and Prevention,United States
H23IP222539,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,39530888,2003,2012,Centers for Disease Control and Prevention,United States
H23IP222534,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,5346605,2003,2012,Centers for Disease Control and Prevention,United States
H23IP222501,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,13795530,2003,2012,Centers for Disease Control and Prevention,United States
H23IP122558,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,11807857,2003,2012,Centers for Disease Control and Prevention,United States
H23IP122555,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,7599557,2003,2012,Centers for Disease Control and Prevention,United States
H23IP122540,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,24289670,2003,2012,Centers for Disease Control and Prevention,United States
H23IP122530,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,7587053,2003,2012,Centers for Disease Control and Prevention,United States
H23IP122529,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,6787449,2003,2012,Centers for Disease Control and Prevention,United States
H23IP122525,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,16585636,2003,2012,Centers for Disease Control and Prevention,United States
H23IP022569,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,7824550,2003,2012,Centers for Disease Control and Prevention,United States
H23IP022550,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,18607916,2003,2012,Centers for Disease Control and Prevention,United States
H23IP022548,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,31860150,2003,2012,Centers for Disease Control and Prevention,United States
H23IP022531,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,9059135,2003,2012,Centers for Disease Control and Prevention,United States
H23IP000790,MISSISSIPPI IMMUNIZATION AND VACCINE GRANT,10058390,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000778,Immunization and Vaccines for Children Program,14692051,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000775,IMMUNIZATION AND VACCINES FOR CHILDREN GRANT,5550667,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000755,IMMUNIZATION AND VACCINES FOR CHILDREN PROGRAM,4430576,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000751,IMMUNIZATIONS AND VACCINE FOR CHILDREN,19247618,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000748,IMMUNIZATIONS AND VACCINES FOR CHILDREN GRANTS,10479382,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000741,Immunization and Vaccines for Children Program,41633856,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000737,MINNESOTA STATEWIDE IMMUNIZATION & VACCINES PROGRAM,15583782,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000733,ARIZONA IMMUNIZATION AND VACCINE FOR CHILDREN,21286744,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000732,IMMUNIZATION AND VACCINES FOR CHILDREN,14626625,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000730,IMMUNIZATION AND VACCINES FOR CHILDREN GRANT,8323787,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000728,NEW JERSEY VACCINE PREVENTABLE DISEASE PROGRAM,22845980,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000727,NEVADA IMMUNIZATION AND VACCINES FOR CHILDREN,9981773,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000723,IMMUNIZATIONS AND VACCINES FOR CHILDREN,16824272,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000719,IMMUNIZATION AND VACCINES FOR CHILDREN PROGRAM,14710428,2013,2017,Centers for Disease Control and Prevention,United States
F32DK008072,EVALUATION OF GENETICALLY ENGINEERED ROTAVIRUS VACCINES,0,1987,1988,National Institute of Diabetes and Digestive and Kidney Diseases,United States
F32AI008222,GROUP B STREPTOCOCCAL OLIGOSACCHARIDE-CONJUGATE VACCINE,0,1991,1991,National Institute of Allergy and Infectious Diseases,United States
F05TW005055,NOVEL APPROACH TOWARD RETROVIRAL VACCINE DESIGN,0,1994,1995,Fogarty International Center,United States
N/A,"Develop low-cost prophylactic vaccines against HCV, and therapeutic vaccines against HBV",9100510,2010,2017,Canadian Institutes of Health Research,Canada
2013-01797,Development of diagnostic tools and vaccines,447887,2013,2015,Swedish Research Council for Environment Agricultural Sciences and Spatial Planning,Sweden
13025B10,Potenzierung von Impfstoffen durch gezieltes Design der Glykosylierung - IPoGly (Impfstoffpotenzierung durch Glykosylierung),377233,2010,2014,Federal Ministry of Education and Research,Germany
01KA1301,"EDCTP: Malaria Vakzine, vorbereitende Arbeiten zur Entwicklung zweier Malaria Impfstoffe",93832,2013,2014,Federal Ministry of Education and Research,Germany
01GU0708,Verbundprojekt: Innovative bakterielle Tumorimpfstoffe - Teilprojekt 1: Bakterielles Prostatakrebsvakzin,766222,2008,2011,Federal Ministry of Education and Research,Germany
SERB_45c964ebaf,Development of Porphyric Intracellular Leishmania Parasite for the Effect vaccine and Vaccine Delivery System,36686,2016,2017,Science and Engineering Research Board,India
2015R1D1A4A01020761,DNA 백신 및 백신보조제 전달을 위한 효율적이고 스마트한 마이크니들시스템 개발,0,2015,2016,National Research Foundation of Korea,South Korea
2015M3A9B5030116,인유두종바이러스 백신 제품화 및 차세대 인유두종바이러스 백신 개발,0,2015,2016,National Research Foundation of Korea,South Korea
2015M3A9B5030142,인유두종바이러스 4가 백신의 제품화 및 인유두종바이러스 10가 백신 개발,0,2015,2016,National Research Foundation of Korea,South Korea
2014R1A6A3A01055315,저온적응 약독 생백신형 만능독감백신 개발 연구,0,2014,2015,National Research Foundation of Korea,South Korea
AF/138/96,Vaccine Biotechnology: Genetically Engineered Chimeric Protein Vaccine Against Foot-and-Mouth Disease,454005,1996,2000,Innovation and Technology Commission,China
2010-00481,Therapeutic cancer vaccine for test in human,526155,2010,2014,VINNOVA,Sweden
156524,The Vaccine Project,15896,2016,2017,Social Sciences and Humanities Research Council,Canada
605578,Ingénierie d'un plateforme vaccinale et développement d'un vaccin vétérinaire contre la gripp,3391,2016,2017,Natural Sciences and Engineering Research Council,Canada
630754,Hepatitis C vaccine preparedness: feasibility of field-based vaccine trials,56978,2010,2012,National Health and Medical Research Council,Australia
272201600035C-0-0-1,A MUCOSAL PROPHYLACTIC VACCINE AGAINST COCCIDIOIDOMYCOSIS,449984,2016,2018,National Institute of Allergy and Infectious Diseases,United States
97F00421,魚類寄生虫に対する遺伝子組換えワクチンおよびDNAワクチンの開発,18068,1998,1999,Japan Society for the Promotion of Science,Japan
16380123,魚類ウイルスを用いたDNAワクチンに代わる新たなRNAワクチンの開発,36058,2004,2004,Japan Society for the Promotion of Science,Japan
11771116,組み換えBCGワクチンシステムを用いた、う蝕予防ワクチンの開発,9665,1999,1999,Japan Society for the Promotion of Science,Japan
00J01507,新規粘膜ワクチンキャリアーの開発およびエイズワクチンへの応用,17502,2000,2001,Japan Society for the Promotion of Science,Japan
N01AI60018-0-0-1,HIV Vaccine Design and Dev. Teams Part A - Preventative Vaccines,3352012,2006,2011,National Institute of Allergy and Infectious Diseases,United States
N01AI60018-0-0-0,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS PART A - PREVENTATIVE VACCINES,3352012,2006,2011,National Institute of Allergy and Infectious Diseases,United States
N01AI50010-0-0-0,"HIV VACCINE DESIGN AND DEVELOPMENT TEAMS, PART B-THERAPEUTIC VACCINES",5042594,2005,2010,National Institute of Allergy and Infectious Diseases,United States
N01AI50009-4-0-0,HIV VACCINES DESIGN &DEVELOPMENT TEAMS-PART B-THERAPEUTIC VACCINE,3418543,2005,2010,National Institute of Allergy and Infectious Diseases,United States
N01AI50008-6-0-1,HIV Vaccines Design and Dev. Teams Part A - Preventative Vaccine,3200598,2008,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI50008-6-0-0,HIV VACCINES DESIGN AND DEVELOPMENT TEAMS PART A - PREVENTATIVE VACCINE,7976947,2005,2010,National Institute of Allergy and Infectious Diseases,United States
N01AI50007-0-0-1,"HIV Vaccine Design and Development, Part A-Preventative Vaccines",1700000,2005,2010,National Institute of Allergy and Infectious Diseases,United States
J3-6363 (D),Priprava tumorskih vakcin: hibridomi in gensko spremenjene vakcine (basic research project),0,2004,2007,Slovenian Research Agency,Slovenia
H23IP000851,"Economics of Vaccines and Immunization Policies, Programs, and Practices for Adults: Prioritysetting for adult vaccines",149989,2014,2016,Centers for Disease Control and Prevention,United States
213682,Nanoparticle delivery systems for cancer vaccines - applications to a MUC1 lipopeptide cancer vaccine,294474,2000,2003,Natural Sciences and Engineering Research Council,Canada
N01AI025480,Millenium Vaccine Initiative-Novel Vaccines for TB and Malaria-26625480,0,2004,2004,National Institute of Allergy and Infectious Diseases,United States
X00120----187043,"現行ワクチンにかわる副作用のない破傷風ワクチンの作成法と, その二種(ジフテリア・破傷風)混合ワクチンへの応用",12432,1976,1976,Japan Society for the Promotion of Science,Japan
G023511N,Evaluatie van afgiftesystemen voor mRNA kanker vaccins,0,2011,2014,Research Foundation - Flanders,Belgium
G007614N,Naar een universeel op mRNA-gebaseerd therapeutisch vaccin tegen HIV,0,2014,2017,Research Foundation - Flanders,Belgium
1210812N,Ontwikkeling van een generische microparticulaire vaccin formulatie,0,2011,2014,Research Foundation - Flanders,Belgium
G003008N,Ontwikkeling van een vaccin tegen Ascaris suum bij het varken.,0,2008,2011,Research Foundation - Flanders,Belgium
81581240327,感染免疫、疫苗与治疗性抗体双边研讨会,12042,2015,2015,National Natural Science Foundation of China,China
80011764,用转基因植物生产口服疫苗,845,2000,2000,National Natural Science Foundation of China,China
60410106426,扫描探针显微学研制细胞免疫疫苗,2053,2004,2004,National Natural Science Foundation of China,China
39940006,疫苗防治人类乳头瘤病毒感染及宫颈癌的研究,6039,1999,1999,National Natural Science Foundation of China,China
39880043,人免疫缺陷病毒多肽疫苗的研究,21740,1999,2001,National Natural Science Foundation of China,China
39780032,肝片吸虫DNA疫苗研究,14488,1998,2000,National Natural Science Foundation of China,China
39680018,新型肝炎病毒基因克隆与DNA疫苗研究,17863,1997,1999,National Natural Science Foundation of China,China
39480022,BCG多价疫苗免疫保护作用的实验研究,11414,1995,1997,National Natural Science Foundation of China,China
39060057,脑包虫细胞系疫苗的研究,5168,1991,1993,National Natural Science Foundation of China,China
39000001,乙型脑炎活疫苗毒株的基因分析,8618,1991,1993,National Natural Science Foundation of China,China
38671111,猪伪狂犬病病毒重组疫苗的研究,6024,1987,1993,National Natural Science Foundation of China,China
30711220434,艾滋病疫苗新型策略与相关免疫学研究,2103,2007,2007,National Natural Science Foundation of China,China
30610103103,疟疾疫苗及其相关基础免疫学的研究,27526,2007,2008,National Natural Science Foundation of China,China
30531160053,鼻咽癌多肽疫苗研究及临床疗效评价,37887,2005,2007,National Natural Science Foundation of China,China
30210103222,新的疟疾疫苗靶点基因的功能研究,3262,2002,2002,National Natural Science Foundation of China,China
30080020,丙型肝炎病毒样颗粒疫苗的基础研究,16909,2001,2003,National Natural Science Foundation of China,China
1356X09,Entwicklung optimaler Herstellungsprozesse artifizieller Malariavakzine,365392,2009,2012,Federal Ministry of Education and Research,Germany
13025A10,Potenzierung von Impfstoffen durch gezieltes Design der Glykosylierung,357548,2010,2013,Federal Ministry of Education and Research,Germany
03VP00510,Kreuzprotektive und thermostabile Humane Papillomavirus Vakzine - T-panHPVvac,1172455,2016,2019,Federal Ministry of Education and Research,Germany
03V0347,Therapeutischer Impfstoff zur Behandlung von Zervixdysplasien,2215626,2012,2016,Federal Ministry of Education and Research,Germany
03FO2211,ForMaT: Diagnostika- und Impfstoffentwicklung für vernachlässigte Infektionskrankheiten,131436,2008,2009,Federal Ministry of Education and Research,Germany
03EFT2BW12,EXIST-Forschungstranfer: Entwicklung eines Impfstoffes gegen Malaria.,569700,2009,2010,Federal Ministry for Economic Affairs and Energy,Germany
031A521,Individualisierte Tumorimpfstoffe mittels eines viralen Vektors,571409,2014,2016,Federal Ministry of Education and Research,Germany
031A144,GO-Bio 5: VEROVACCINES - Tierimpfstoffe auf Hefebasis,3935142,2013,2018,Federal Ministry of Education and Research,Germany
315241,"BioPharma: Allianz für Antiinfektiva, Chemotherapeutika und Impfstoffe",146344,2008,2008,Federal Ministry of Education and Research,Germany
01KA1501,EDCTP: Malaria-Impfstoff-Entwicklung: zwei EDCTP Projekte,15864,2015,2015,Federal Ministry of Education and Research,Germany
SERB_968aca715e,Identification Of Novel Targets For Effective Drugs/Vaccines Against,43096,2017,2018,Science and Engineering Research Board,India
BCTR9903159,MUC1 as a Potential Breast Cancer Vaccine,248741,1999,2002,Susan G. Komen Breast Cancer Foundation,United States
N/A,Centre for Nano-vaccines (sagsnr.: 09-067052),4424845,2010,2015,Danish Ministry of Higher Education and Science,Denmark
627315,Oncolytic virus vaccine to cure different kinds of cancer,3463,2017,2018,Natural Sciences and Engineering Research Council,Canada
627268,Screening for immunogenic antigens for Zika virus vaccine,3463,2017,2018,Natural Sciences and Engineering Research Council,Canada
627088,Oncolytic virus vaccine to cure different kinds of cancer,3463,2017,2018,Natural Sciences and Engineering Research Council,Canada
627087,Oncolytic virus vaccine to cure different kinds of cancer,3463,2017,2018,Natural Sciences and Engineering Research Council,Canada
621083,Single-walled carbon nanotubes as delivery vehicle of vaccines,16174,2017,2018,Natural Sciences and Engineering Research Council,Canada
642507,Bioprocess Sciences and Technology of Viral Vaccines,154056,2017,2018,Natural Sciences and Engineering Research Council,Canada
N/A,Antigen Discovery for Human Helminth Vaccines Using Immunomics,0,2012,2012,Council for International Exchange of Scholars,United States
N/A,Vaccines That Induce Broadly Protective Antibodies Against Influenza,0,2017,2017,Council for International Exchange of Scholars,United States
N/A,Quillaja Saponin Adjuvants in Carbohydrate Cancer Vaccines,0,2010,2012,Council for International Exchange of Scholars,United States
N/A,Indo-U.S. Asthma Research Collaborative Group: Asthma Vaccine,0,2008,2008,Council for International Exchange of Scholars,United States
N/A,Quillaja Saponin Adjuvants in Carbohydrate Cancer Vaccines,0,2010,2012,Council for International Exchange of Scholars,United States
N/A,Development of a Recombinant DNA Vaccine Against Blackleg,0,2011,2012,Council for International Exchange of Scholars,United States
N/A,Toward Enhanced Pulmonary Delivery of Vaccines,0,2006,2007,Council for International Exchange of Scholars,United States
O3/IN3/B364STAR05,Developing a prototype MMR vaccine,15347,2005,2005,Science Foundation Ireland,Ireland
N/A,Lactococcus lactis live vaccines against leishmaniasis,14769,2005,2006,Canadian Institutes of Health Research,Canada
N/A,Strategic training program in vaccine development and delivery,3184,2002,2002,Canadian Institutes of Health Research,Canada
N/A,Needle-free Vaccines for Respiratory Viruses,346628,2002,2004,Canadian Institutes of Health Research,Canada
N/A,Development of proteosome-based vaccines for protozoan pathogens,63651,2001,2003,Canadian Institutes of Health Research,Canada
N/A,Mechanisms of dendritic cell-based cancer vaccines,235501,2002,2007,Canadian Institutes of Health Research,Canada
N/A,CIHR Team in Structure-Based Vaccine Design,7556,2006,2006,Canadian Institutes of Health Research,Canada
N/A,Transferring binding regions as vaccine agents,71400,2003,2004,Canadian Institutes of Health Research,Canada
N/A,Structural studies on antiidiotypic antibody vaccines,27317,1998,2001,Canadian Institutes of Health Research,Canada
N/A,Vaccine antigens for C. pneumoniae atherosclerosis,28049,1999,2000,Canadian Institutes of Health Research,Canada
N/A,Development of a Vaccine Against Canine Leishmaniasis,64572,2001,2002,Canadian Institutes of Health Research,Canada
N/A,Novel Dendritic Cell-based Vaccine of Cancer,66623,2004,2008,Canadian Institutes of Health Research,Canada
N/A,Human alloimmune responses and HIV-1 vaccine development,0,1998,2001,Canadian Institutes of Health Research,Canada
N/A,Transdermal delivery systems for protein medicines and vaccines,107932,2004,2006,Canadian Institutes of Health Research,Canada
N/A,Towards a Type 1 Diabetes Vaccine,63697,2002,2003,Canadian Institutes of Health Research,Canada
N/A,Cancer Vaccines: Targeting Cancer Genes for Immunotherapy,3017,2016,2016,Canadian Cancer Society,Canada
N/A,The role of Alloimmunization in HIV vaccine design,35506,1996,2001,Canadian Institutes of Health Research,Canada
N/A,Development of a novel intranasal vaccine against measles,68775,2003,2005,Canadian Institutes of Health Research,Canada
N/A,A DNA vaccine for chlamydia trachomatis,103437,2001,2004,Canadian Institutes of Health Research,Canada
N/A,Delivery of genetic vaccines through Microporated Skin,32616,2002,2003,Canadian Institutes of Health Research,Canada
N/A,Post-genomic studies of BCG vaccines,332091,1999,2005,Canadian Institutes of Health Research,Canada
N/A,Transcutaneous vaccines: Delivery and mechanisms of immune induction,56581,2000,2002,Canadian Institutes of Health Research,Canada
SERB_44e315abd3,Aptamer-mRNA Chimera-The Next Generation RNA vaccine,60383,2016,2017,Science and Engineering Research Board,India
211394,nd,1514,2016,2017,Fonds de Recherche du Québec – Nature et technologies,Canada
34259,Déterminants des couvertures vaccinales chez les enfants âgés de 1 an et 2 ans au Québec et impact épidémiologique des retards vaccinaux,29817,2016,2017,Fonds de Recherche du Québec - Santé,Canada
9955,DEVELOPMENT OF DNA VACCINES AGAINST CUTANEOUS T CELL LYMPHOMA,113067,2000,2003,Bloodwise,United Kingdom
9803,DNA VACCINES AS INDUCERS OF IMMUNITY AGAINST  HAEMATOLOGICAL MALIGNANCIES,746244,1998,1999,Bloodwise,United Kingdom
2015R1D1A1A02062348,미세막상 구조물을 이용한 비세포 항암 백신,0,2015,2016,National Research Foundation of Korea,South Korea
2015K1A3A7A03073714,차세대 결핵백신의 방어면역 바이오마커 발굴,0,2015,2016,National Research Foundation of Korea,South Korea
2013R1A2A1A03069903,다제내성 결핵을 표적으로 하는 치료백신 개발연구,0,2013,2014,National Research Foundation of Korea,South Korea
2012R1A1A1042735,다공성 실리카 나노입자를 이용한 암백신 전달체 연구,0,2012,2013,National Research Foundation of Korea,South Korea
2012R1A2A2A06045773,스마트 백신 경피 제형 및 레이저 면역보조제 개발,0,2012,2013,National Research Foundation of Korea,South Korea
2013K1A2A1043459,개발 도상국을 위한 백신 개발 지원 프로그램,0,2013,2014,National Research Foundation of Korea,South Korea
2014R1A2A1A11051899,유산균 항원운반체를 매개로 하는 급여형어류백신 개발 연구,0,2014,2015,National Research Foundation of Korea,South Korea
2010-00167,새로운 결핵 생백신 후보 물질의 개발 및 분석,0,2010,2011,National Research Foundation of Korea,South Korea
2011-0009339,Terpene 성분을 이용한 진균백신 개발,0,2011,2012,National Research Foundation of Korea,South Korea
2011-0015258,새로운 결핵 생백신 후보 물질의 개발 및 분석,0,2011,2012,National Research Foundation of Korea,South Korea
2010-0030044,신규 결핵예방백신 개발사업 기획연구,0,2010,2011,National Research Foundation of Korea,South Korea
2010-00713,새로운 결핵 생백신 후보 물질의 개발 및 분석,0,2010,2011,National Research Foundation of Korea,South Korea
2015361,H. pylori infection and oral enteric vaccines,60000,2015,2017,United States-Israel Binational Science Foundation,Israel
InP/038/15,A New Therapeutic Vaccine for HIV/AIDS,26697,2015,2016,Innovation and Technology Commission,China
ITS/194/13,A New Therapeutic Vaccine for HIV/AIDS,179388,2014,2016,Innovation and Technology Commission,China
N/A,Generation of HyperImmunogenic vaccines against human viral pathogens,881665,2013,2013,Danish Agency for Science and Higher Education,Denmark
N/A,Delivery of vaccine antigens on virus like particles,385160,2016,2016,Danish Agency for Science and Higher Education,Denmark
N/A,Less is more in TB vaccines,449644,2017,2017,Danish Agency for Science and Higher Education,Denmark
VM0104,Development of a potency test for leptospira vaccines,292991,1993,1996,Department for Environment Food and Rural Affairs,United Kingdom
SE3218,"Bovine TB vaccine programme advisor, Prof Douglas Young",105796,2003,2011,Department for Environment Food and Rural Affairs,United Kingdom
SE2912,Improved selection methods for emergency FMD vaccines,810873,1997,2000,Department for Environment Food and Rural Affairs,United Kingdom
SE2901,Improved selection methods for emergency FMD vaccines,652432,1994,1996,Department for Environment Food and Rural Affairs,United Kingdom
SE2804,Protective immune responses induced by FMDV vaccine,256438,1996,1999,Department for Environment Food and Rural Affairs,United Kingdom
SE2803,Antigenic properties of vaccine virus strains,232602,1993,1996,Department for Environment Food and Rural Affairs,United Kingdom
OZ0131,Live salmonella vaccines for the protection of poultry,185946,1997,1998,Department for Environment Food and Rural Affairs,United Kingdom
OZ0115,"`The development of live, rationallyattenuated salmonella vaccines`",653455,1994,1997,Department for Environment Food and Rural Affairs,United Kingdom
617355,Bioprocess Sciences and Technology of Viral Vaccines,150889,2016,2017,Natural Sciences and Engineering Research Council,Canada
606102,Synthesis of a Potential Lyme Disease Vaccine,3391,2016,2017,Natural Sciences and Engineering Research Council,Canada
602424,Oncolytic virus vaccine to cure different kinds of cancer,3391,2016,2017,Natural Sciences and Engineering Research Council,Canada
602423,Oncolytic virus vaccine to cure different kinds of cancer,3391,2016,2017,Natural Sciences and Engineering Research Council,Canada
602422,Oncolytic virus vaccine to cure different kinds of cancer,3391,2016,2017,Natural Sciences and Engineering Research Council,Canada
598373,Targeted microneedle insertion for epidermal vaccine delivery and biosensing,37718,2016,2017,Natural Sciences and Engineering Research Council,Canada
LY13H100003,FcR介导的具有特异免疫保护作用新型RSV粘膜疫苗的研究,0,2013,2017,Science and Technology Department of Zhejiang Province,China
17K16224,Development of RNA vaccine against dengue virus infection,37533,2017,2019,Japan Society for the Promotion of Science,Japan
940158,Construction of designer immunogens for use as vaccines,441609,1994,1998,National Health and Medical Research Council,Australia
890035,Development of a possible vaccine for gonorrhoea,72348,1989,1991,National Health and Medical Research Council,Australia
880846,Designing novel chemicals as potential influenza vaccines,70796,1988,1990,National Health and Medical Research Council,Australia
930141,An improved vaccine for hepatitis B virus,111817,1993,1995,National Health and Medical Research Council,Australia
971242,Schistosome proteolytic enzymes as drug and vaccine tar gets,69224,1997,1997,National Health and Medical Research Council,Australia
900170,Development of a vaccine to prevent malaria transmissio n,197208,1990,1992,National Health and Medical Research Council,Australia
910347,Development of AIDS vaccine using synthesized peptides.,123855,1991,1994,National Health and Medical Research Council,Australia
8118,Factors affecting the immunogenicity of pertussis vaccines,29704,2000,2001,National Health and Medical Research Council,Australia
900771,Search for active components for a malaria vaccine,203274,1990,1992,National Health and Medical Research Council,Australia
930123,The development of a safer whooping cough vaccine,99460,1993,1995,National Health and Medical Research Council,Australia
950472,Towards a vaccine against infantile diarrhoeal disease,171630,1995,1998,National Health and Medical Research Council,Australia
990037,Development of a Plant-Derived Oral Vaccine for Measles,111784,1999,2001,National Health and Medical Research Council,Australia
987521,Development of a nucleic acid vaccine for schistosomiasis,37292,1998,2001,National Health and Medical Research Council,Australia
284535,"Intestinal adapatation, Intususspection and rotavirus vaccine, applied clinical nutrition",170570,2004,2008,National Health and Medical Research Council,Australia
284475,Bacterial delivery of DNA vaccines: salmonella - endosome interactions,8896,2004,2004,National Health and Medical Research Council,Australia
437000,Clinical trials of RV3 oral human neonatal rotavirus vaccine,160408,2007,2011,National Health and Medical Research Council,Australia
418108,CD8+ T cell immunity to viruses and recombinant vaccines,414742,2007,2011,National Health and Medical Research Council,Australia
930841,How to turn malaria proteins into a vaccine,60047,1993,1993,National Health and Medical Research Council,Australia
981340,A cytotoxic T cell epitope based vaccine for HIV,199095,1998,2000,National Health and Medical Research Council,Australia
970804,The development of an oral whooping cough vaccine,106640,1997,1999,National Health and Medical Research Council,Australia
890949,Why are live vaccines often better than killed?,109212,1989,1991,National Health and Medical Research Council,Australia
931125,Relevance of bacterial surface structure to vaccine dev elopment,149976,1993,1995,National Health and Medical Research Council,Australia
OPP1025596,To develop and test a DNA vaccine for HIV,100000,2010,2012,Bill & Melinda Gates Foundation,United States
OPP1070514,To develop novel vesicle-derived vaccines against Mycobacterium tuberculosis.,440000,2012,2015,Bill & Melinda Gates Foundation,United States
OPP37868,To develop nanoemulsions and adjuvants for nasal-spray vaccines,6294086,2005,2012,Bill & Melinda Gates Foundation,United States
OPP1094567,To support CMV vector-based Vaccine Concept,2871805,2013,2016,Bill & Melinda Gates Foundation,United States
OPP37881,To develop an inexpensive therapeutic vaccine for human papillomavirus,3543549,2005,2013,Bill & Melinda Gates Foundation,United States
OPP1154635,To produce better and cheaper vaccines against polio,1847820,2016,2018,Bill & Melinda Gates Foundation,United States
OPP38637,To fund a vaccine discovery (antibody) consortium,25293370,2006,2013,Bill & Melinda Gates Foundation,United States
OPP1084286,To conduct a pneumococcal vaccine impact assessment in Bangladesh,6376130,2013,2019,Bill & Melinda Gates Foundation,United States
OPP38580,To develop a Global HIV Vaccine Research Cryorepository (GHRC),7782675,2006,2009,Bill & Melinda Gates Foundation,United States
OPP1148786,To test a novel universal influenza vaccine,385144,2016,2017,Bill & Melinda Gates Foundation,United States
OPP633,To develop a genetically engineered recombinant hookworm vaccine,18000000,2000,2006,Bill & Melinda Gates Foundation,United States
OPP33112,To conduct an analysis of pediatric enteric vaccine development,807080,2004,2005,Bill & Melinda Gates Foundation,United States
OPP1002555,To develop a unique delivery system for vaccines whose major health impact is in high burden countries allowing the conversion of existing injectable vaccines into oral and/or inhalation vaccines and expedite development of novel mucosal vaccines,804741,2011,2014,Bill & Melinda Gates Foundation,United States
X46120-----70030,狂犬病日卵ワクチンの改良,5178,1971,1971,Japan Society for the Promotion of Science,Japan
X46120-----70025,ボツリヌス中毒の経口ワクチンに関する研究,8287,1971,1971,Japan Society for the Promotion of Science,Japan
X46120-----70036,インフルエンザワクチンの改善に関する研究,11740,1971,1971,Japan Society for the Promotion of Science,Japan
X42120-----71124,インフルエンザ生ワクチンに関する研究(継2年),6768,1967,1967,Japan Society for the Promotion of Science,Japan
X43120-----71029,流行性耳下膜炎生ワクチンに関する研究,6906,1968,1968,Japan Society for the Promotion of Science,Japan
X00120----670025,ボッリヌス中毒の経口ワクチンに関する研究,6906,1972,1972,Japan Society for the Promotion of Science,Japan
X00120----670036,インフルエンザワクチンの改善に関する研究,8978,1972,1972,Japan Society for the Promotion of Science,Japan
X00120----787028,精製三種混合(D.T.P)ワクチンの試験的研究,17265,1972,1973,Japan Society for the Promotion of Science,Japan
X00120----387007,精製狂犬病ワクチンによる咬傷後免疫法の研究,17956,1978,1979,Japan Society for the Promotion of Science,Japan
X00120----187046,水痘生ワクチンの開発に関する研究,10360,1976,1976,Japan Society for the Promotion of Science,Japan
X00120----087080,水痘生ワクチンの開発に関する研究,12914,1975,1975,Japan Society for the Promotion of Science,Japan
X00120----587054,大腸菌K1株のワクチン開発研究,24172,1980,1980,Japan Society for the Promotion of Science,Japan
X00090----856161,緑膿菌の溶解ワクチンに関する研究,9323,1973,1973,Japan Society for the Promotion of Science,Japan
99J03631,SHIVを用いたAIDS弱毒生ワクチンの間発,31546,1999,2001,Japan Society for the Promotion of Science,Japan
98F00138,腸管寄生虫に対する粘膜ワクチンの開発,16256,1999,2000,Japan Society for the Promotion of Science,Japan
58771559,HB ワクチンによる歯科医師のB型肝炎予防対策について,6213,1983,1983,Japan Society for the Promotion of Science,Japan
58480395,抗齲蝕ワクチン開発に関する基礎的研究,42130,1983,1984,Japan Society for the Promotion of Science,Japan
56870053,肺炎球菌ワクチンの実用化に関する研究,11740,1981,1981,Japan Society for the Promotion of Science,Japan
57015012,抗原特異的抗腫瘍ワクチンの開発とその応用,22102,1982,1982,Japan Society for the Promotion of Science,Japan
22790870,DNAワクチンによる自己免疫性糖尿病の寛解,14803,2010,2010,Japan Society for the Promotion of Science,Japan
22240057,Programmed Activationに基づく人工DNAワクチンの創製,183583,2010,2010,Japan Society for the Promotion of Science,Japan
19790430,乳幼児におけるインフルエンザワクチンに対する免疫原性に関する研究,11034,2007,2007,Japan Society for the Promotion of Science,Japan
4760137,遺伝子組換えによるせっそう病トキソイドワクチンの開発,7104,1992,1992,Japan Society for the Promotion of Science,Japan
3857253,MHC非拘束性合成う蝕ワクチンの研究,6688,1991,1991,Japan Society for the Promotion of Science,Japan
2857269,蛋白質工学を利用した蝕ワクチンの分子設計,7597,1990,1990,Japan Society for the Promotion of Science,Japan
2856074,鶏コクシジウムのコンポーネント・ワクチンに関する基礎的研究,4833,1990,1990,Japan Society for the Promotion of Science,Japan
1790488,家禽に対する遺伝子組み換えウィルスワクチン用ベクターに関する研究,13118,1989,1990,Japan Society for the Promotion of Science,Japan
592381,Bioprocess Sciences and Technology of Viral Vaccines,156508,2015,2016,Natural Sciences and Engineering Research Council,Canada
580413,Stability of a dry whole cell malaria vaccine,3518,2015,2016,Natural Sciences and Engineering Research Council,Canada
581150,Excipient investigation for improving Herpes simpex II vaccine processing,3518,2015,2016,Natural Sciences and Engineering Research Council,Canada
577324,Targeted microneedle insertion for epidermal vaccine delivery and biosensing,39124,2015,2016,Natural Sciences and Engineering Research Council,Canada
hrc_7d782a16,Novel vaccine approaches for protecting against helminth parasites,927884,2010,2013,Health Research Council of New Zealand,New Zealand
hrc_85e8ff70,Immunisation disparities and vaccine-preventable diseases in New Zealand,90826,2008,2011,Health Research Council of New Zealand,New Zealand
ASTHMARF02L,T cell vaccines for asthma and allergic rhinitis,435809,2001,2006,Asthma UK,United Kingdom
N01AI95367-0-0-1,Clinical Grade H9N2 Influenza Vaccine,0,1999,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI60023-3-0-0,NIAID HIV VACCINE RESEARCH EDUCATION INITIATIVE,2685906,2006,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI60007-4-0-1,Simian Vaccine Evaluation Units,4388000,2008,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI60007-4-0-0,SIMIAN VACCINE EVALUATION UNIT,2090968,2006,2013,National Institute of Allergy and Infectious Diseases,United States
N01AI60006-4-0-1,Simian Vaccine Evaluation Unit (SVEU),3464000,2008,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI60006-4-0-0,SIMIAN VACCINE EVALUATION UNIT,6720850,2006,2013,National Institute of Allergy and Infectious Diseases,United States
N01AI60005-5-0-1,Simian Vaccine Evaluation Unit (SVEU),6369000,2008,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI60005-5-0-0,SIMIAN VACCINE EVALUATION UNIT,4640567,2006,2013,National Institute of Allergy and Infectious Diseases,United States
N01AI50041-5-0-1,Tularemia Vaccine Development Team,0,2005,2010,National Institute of Allergy and Infectious Diseases,United States
N01AI50041-5-0-0,TULAREMIA VACCINE DEVELOPMENT TEAM,6978780,2005,2010,National Institute of Allergy and Infectious Diseases,United States
N01AI50040-5-0-0,TULAREMIA VACCINE DEVELOPMENT TEAM,4000000,2005,2010,National Institute of Allergy and Infectious Diseases,United States
N01AI50010-0-0-1,HIV Vaccine Design and Development Teams,5042594,2005,2010,National Institute of Allergy and Infectious Diseases,United States
N01AI40091-8-0-1,Tuberculosis Research Materials and Vaccine Testing,515844,2008,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI40091-8-0-0,TUBERCULOSIS RESEARCH MATERIALS AND VACCINE TESTING,4270280,2004,2011,National Institute of Allergy and Infectious Diseases,United States
N01AI30053-0-0-1,Production and Testing of Anthrax Vaccine,0,2003,2007,National Institute of Allergy and Infectious Diseases,United States
N01AI30031-0-0-1,HIV Vaccine Design and Development Teams,1300000,2003,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI30030-0-0-1,HIV Vaccine Design and Development Teams,2600000,2003,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI25464-13-0-2,Vaccine and Treatment Evaluation Unit,791496,2002,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI25453-2-0-1,Vaccine and Treatment Evaluation Unit,17271,2001,2006,National Institute of Allergy and Infectious Diseases,United States
N01AI05421-27-0-1,Malaria Vaccine Production and Support Services,5293544,2008,2008,National Institute of Allergy and Infectious Diseases,United States
N01AI05421-27-0-0,MALARIA VACCINE PRODUCTION AND SUPPORT SERVICES,4312612,2000,2014,National Institute of Allergy and Infectious Diseases,United States
52068,Molecular analysis of immune responses to malaria peptide vaccines,149592,1998,2000,Swiss National Science Foundation,Switzerland
66442,Immunologische Kontrolle der Zeckeninduzierten Immunmodulation: Eine Vakzinestrategie.,0,2001,2002,Swiss National Science Foundation,Switzerland
40199,Conserved CTL Epitopes in HIV-1 as Potential Vaccines.,29019,1994,1995,Swiss National Science Foundation,Switzerland
37440,Biodegradable microspheres as a novel vaccine delivery system,142572,1994,1997,Swiss National Science Foundation,Switzerland
36349,Development of a vaccine against HELICOBACTER PYLORI infection,307034,1993,1995,Swiss National Science Foundation,Switzerland
CRUK-A7825,Robo4 protein as a cancer vaccine,0,2007,2008,Cancer Research UK,United Kingdom
Y205749,肾综合征出血热基因工程疫苗的研制,0,2005,2013,Science and Technology Department of Zhejiang Province,China
Y204458,麻疹流行株的抗原变异对疫苗效果影响的研究,0,2004,2012,Science and Technology Department of Zhejiang Province,China
LQ13C180002,基于蛋白质组学的兔支气管败血波氏杆菌反向疫苗学研究,0,2013,2016,Science and Technology Department of Zhejiang Province,China
Y305031,PRRS多价基因工程疫苗研究的新策略,0,2005,2009,Science and Technology Department of Zhejiang Province,China
DRT-S97-19,Breast Cancer Vaccines from Plants,51865,1998,2000,UC Discovery Grants (formerly IUCRP),United States
DRT-S96-10,Basic Studies in Super Vaccines,54650,1997,1998,UC Discovery Grants (formerly IUCRP),United States
DRT-biostar00-10098,Vaccines Based on DNA Adenine Methylase Technology,127444,2001,2002,UC Discovery Grants (formerly IUCRP),United States
DRT-S97-25,Mechanism of action of DNA vaccines,212413,1998,2000,UC Discovery Grants (formerly IUCRP),United States
3853,Development of a novel carrier/adjuvant for intranasal vaccines,117981,2004,2006,Israel Science Foundation,Israel
9-2000-1012,Australia III - DVDC  (Diabetes Vaccine Development Center),8965963,2004,2014,Juvenile Diabetes Research Foundation,United States
141321,Improving whole-organism vaccines against malaria by genetic modification,0,2016,2018,Foundation for Science and Technology,Portugal
208297,AquaSolve: Nanobead vaccine delivery platform for aquaculture,355035,2011,2012,The Research Council of Norway,Norway
217391,Effective vaccine against winter ulcer in salmon.,272177,2012,2013,The Research Council of Norway,Norway
187664,Low cost production of biopharmaceuticals and vaccines in plants,8529,2007,2007,The Research Council of Norway,Norway
M1-0150 (C),Rekombinantno cepivo proti aviarni influenci,0,2006,2007,Slovenian Research Agency,Slovenia
96/11539-0,Development of a recombinant BCG vaccine - DPT,0,1997,2000,São Paulo Research Foundation,Brazil
94/05878-1,Peptides and proteins for vaccines and therapeutics,0,1995,1996,São Paulo Research Foundation,Brazil
CBD99-020,Development of Naked DNA Vaccine: Brucella,70000,1998,1999,United States Department of Defense,United States
5578,Preparation of liquid live vaccine against rubella,233401,2008,2010,Slovak Research and Development Agency,Slovakia
72284,Construction and characterization of live-attenuated enterobacterial vaccine candidates,55902,2008,2011,Hungarian Scientific Research Fund,Hungary
561463,Evaluation of an oncolytic vaccine in dogs,4071,2014,2015,Natural Sciences and Engineering Research Council,Canada
557753,Bioprocess Sciences and Technology of Viral Vaccines,90554,2014,2015,Natural Sciences and Engineering Research Council,Canada
563155,Targeted microneedle insertion for epidermal vaccine delivery and biosensing,45275,2014,2015,Natural Sciences and Engineering Research Council,Canada
150026,Controlled Release Nanoparticle vaccines,2736860,2005,2010,Innovate UK,United Kingdom
2101,Novel dendritic cell-based vaccine of cancer,67080,2004,2007,Saskatchewan Health Research Foundation,Canada
2093,Transdermal delivery systems for protein medicines and vaccines,72594,2004,2006,Saskatchewan Health Research Foundation,Canada
2094,Transdermal delivery systems for protein medicines and vaccines,37264,2004,2005,Saskatchewan Health Research Foundation,Canada
QLK2-CT-1999-01321,European vaccine effort against hiv/aids,9080219,2000,2005,European Commission,Belgium
BIO4980031,Biosafety of vaccines based on self-replicating recombinant alphavirus,0,1998,2000,European Commission,Belgium
IC18980387,Selection of P. Falciparum antigene for MPES vaccine development,0,1999,2001,European Commission,Belgium
CIPA940230,New approaches for the development of enterobacterial vaccine strains,0,1995,1997,European Commission,Belgium
CIPE926123,Development of vaccines against coccidiosis through biotechnology,0,1993,1994,European Commission,Belgium
TS3*930255,Oral vaccine against cholera with Built-in adjuvanticity,0,1994,1997,European Commission,Belgium
TS1*0026,CHEMICAL SYNTHESIS OF HEPATITIS B VACCINES,0,1984,1986,European Commission,Belgium
MR4*0027,DEVELOPMENT OF AN EFFICIENT VACCINE (AIDS),0,1987,1988,European Commission,Belgium
TS2*0188,DEVELOPMENT OF SYNTHETIC VACCINES AGAINST NEMATODE INFECTIONS,0,1989,1993,European Commission,Belgium
TS2*0218,DEVELOPMENT OF VACCINE AGAINST CHAGAS' DISEASE,0,1989,1992,European Commission,Belgium
U01CK000350,EVAL OF IMPCT OF JAPANESE ENCEPHALITIS VACCINE IN CAMBODIA,75190,2014,2015,Centers for Disease Control and Prevention,United States
101143,Rational design of an AIP56-based anti-pasteurellosis vaccine,145174,2010,2013,Foundation for Science and Technology,Portugal
103484,Exploring pathogen diversity in disease epidemiology and vaccine research,217382,2010,2013,Foundation for Science and Technology,Portugal
113650,Melhoramento da imunogenicidade de vacinas de DNA,163587,2011,2013,Foundation for Science and Technology,Portugal
61090,Development of DNA vaccine prototypes for veterinary trypanosomiasis,83746,2005,2007,Foundation for Science and Technology,Portugal
82211,Development of DNA vaccine prototypes for veterinary trypanosomiasis,32656,2007,2009,Foundation for Science and Technology,Portugal
126635,Anti-ghrelin vaccine: a feasible alternative for obesity treatment?,66351,2013,2014,Foundation for Science and Technology,Portugal
116097,Smart porous particles for pulmonary drug and vaccine delivery,116280,2011,2014,Foundation for Science and Technology,Portugal
65048,Impact of the conjugate pneumococcal vaccines on pneumococcal ecology,208503,2009,2012,Foundation for Science and Technology,Portugal
70275,Vaccine potential of different Leishmania infantum proteins,148018,2007,2011,Foundation for Science and Technology,Portugal
152995,Development of subunit anti-viral vaccines for salmonid fish,142445,1998,2000,Natural Sciences and Engineering Research Council,Canada
84171,Towards a live vaccine against cryptobiosis in salmonids,9540,1991,1993,Natural Sciences and Engineering Research Council,Canada
111908,Développement d'un vaccin contre Streptococcus suis,52358,1997,1998,Natural Sciences and Engineering Research Council,Canada
54872,Enhancing vaccine efficacy by molecular chimerization to cytokines,15503,1993,1994,Natural Sciences and Engineering Research Council,Canada
66199,"Development of vaccines for BVDV, BRSV and PI-3",78576,1991,1993,Natural Sciences and Engineering Research Council,Canada
214798,Development of vaccine vector for human immunodeficiency virus,22291,2002,2003,Natural Sciences and Engineering Research Council,Canada
325113,Identification of tumor-associated antigens as cancer vaccine targets,129424,2005,2007,Natural Sciences and Engineering Research Council,Canada
176289,Design of a glycoconjugate vaccine against group A streptococcus,129905,1999,2001,Natural Sciences and Engineering Research Council,Canada
98132,Development of a subunit vaccine for haemophilus somnus,43628,1991,1992,Natural Sciences and Engineering Research Council,Canada
54871,Increasing vaccine efficiency through defined adjuvant use,128223,1992,1994,Natural Sciences and Engineering Research Council,Canada
212544,Design of a glycoconjugate vaccine against group A streptococcus,23745,2002,2003,Natural Sciences and Engineering Research Council,Canada
78064,Development of a multivalent recombinant fowlpox virus vaccine,161733,1991,1993,Natural Sciences and Engineering Research Council,Canada
9534,Development of a molecularly defined vaccine for Myxosporean parasites,116966,1995,1997,Natural Sciences and Engineering Research Council,Canada
472024,Role of TLR4 binding adjuvant in improving cancer vaccines,4090,2010,2011,Natural Sciences and Engineering Research Council,Canada
298504,Attenuating West Nile: The search for a Love Vaccine,14278,2005,2006,Natural Sciences and Engineering Research Council,Canada
240074,Development of porcine adenovirus-3 as a vaccine vector,373818,2000,2004,Natural Sciences and Engineering Research Council,Canada
330272,Attenuating West Nile: The search for a Love Vaccine,15247,2006,2007,Natural Sciences and Engineering Research Council,Canada
408862,Recombinant fowl adenovirus based vaccine against avian influenza,4216,2008,2009,Natural Sciences and Engineering Research Council,Canada
372020,Novel biodegradeable hydrogel for hiv vaccine delivery,16102,2007,2008,Natural Sciences and Engineering Research Council,Canada
53574,Human adenovirus-based vaccines and mammalian expression vectors,351165,1991,1994,Natural Sciences and Engineering Research Council,Canada
239917,Oral vaccines: Targetting to improve induction of mucosal immunity,298383,1999,2004,Natural Sciences and Engineering Research Council,Canada
442602,Diagnostics of fish diseases and development of vaccines,3939,2009,2010,Natural Sciences and Engineering Research Council,Canada
51493,Development of a recombinant vaccine for porcine transmissible gastroenteritis,243286,1991,1994,Natural Sciences and Engineering Research Council,Canada
57603,Development of an effective recombinant Actinobacillus pleuropneumoniae vaccine,206369,1991,1994,Natural Sciences and Engineering Research Council,Canada
152504,Liposome-cytokine formulations as vaccine delivery systems,59485,1996,2000,Natural Sciences and Engineering Research Council,Canada
518456,Synthesis of cyclic oligonucleotide analogues as mucosal vaccine adjuvants,3654,2012,2013,Natural Sciences and Engineering Research Council,Canada
368324,Creating edible forage-based vaccines against bovine pneumonic pasteurellosis,408329,2004,2008,Natural Sciences and Engineering Research Council,Canada
429473,Novel Multi-Strain Vaccines against HIV-1,17520,2009,2010,Natural Sciences and Engineering Research Council,Canada
254432,Development of vaccine vector for human immunodeficiency virus,292,2003,2004,Natural Sciences and Engineering Research Council,Canada
327282,Novel Multi-Strain Vaccines against HIV-1,8812,2006,2007,Natural Sciences and Engineering Research Council,Canada
492,Development of a bovine adenovirus vaccine vector,216848,1994,1997,Natural Sciences and Engineering Research Council,Canada
369571,Novel Multi-Strain Vaccines against HIV-1,27926,2007,2008,Natural Sciences and Engineering Research Council,Canada
467118,In vitro qualification of a SPIO labeled vaccine,4090,2010,2011,Natural Sciences and Engineering Research Council,Canada
470801,Evaluation of fowl adenovirus based recombinant vaccines for poultry,4363,2010,2011,Natural Sciences and Engineering Research Council,Canada
187874,Development of vaccine vector for human immunodeficiency virus,22598,2001,2002,Natural Sciences and Engineering Research Council,Canada
328626,Development of Synthetic Glycoconjugate Vaccines for Active Tumor Immunotherapy,18511,2006,2007,Natural Sciences and Engineering Research Council,Canada
370582,Development of Synthetic Glycoconjugate Vaccines for Active Tumor Immunotherapy,19546,2007,2008,Natural Sciences and Engineering Research Council,Canada
502258,Optimization of vaccine production in algae using engineered bioreactors,17498,2012,2013,Natural Sciences and Engineering Research Council,Canada
467031,Développement d'un vaccin atténué contre la colibacillose aviaire,29109,2010,2011,Natural Sciences and Engineering Research Council,Canada
293470,The Effects of Chemotherapy on Gene-Based Cancer Vaccines,14442,2005,2006,Natural Sciences and Engineering Research Council,Canada
487216,Développement d'un vaccin atténué contre la colibacillose aviaire,30328,2011,2012,Natural Sciences and Engineering Research Council,Canada
Z01RR010444,UPDATING COMPUTER FACILITIES FOR THE VACCINE LABORATORY,0,1994,1994,National Center for Advancing Translational Sciences,United States
Y1AI2642-11-0-1,HIV Vaccine Research and Development,22663000,2008,2008,National Institute of Allergy and Infectious Diseases,United States
U51IP000821,INTRODUCING THE USE OF SEASONAL INFLUENZA VACCINES,696000,2013,2016,Centers for Disease Control and Prevention,United States
U38IP522352,Enhanced surveillance for newly vaccine preventable disease,0,2002,2007,Centers for Disease Control and Prevention,United States
U18FD004012,Discovery of Biological and Immunological Biomarkers for TB Vaccines,299525,2010,2014,United States Food and Drug Administration,United States
U10CI923373,STUDYING THE MEASLES INFECTIONS &DEVELOPMENT OF MEASLES VACCINES,0,2003,2007,Centers for Disease Control and Prevention,United States
U01FD004575,Innovations in Vaccine Clinical Trials and Pharmacovigilance,1492900,2012,2017,United States Food and Drug Administration,United States
U01FD004248,SUPPORTING INFLUENZA VACCINE INTRODUCTION IN LOW-MIDDLE INCOME COUNTRIES,1373500,2011,2017,United States Food and Drug Administration,United States
U01AI037543,EPITOPE POLYMORPHISM IN P FALCIPARUM VACCINE ANIGENS,0,1994,1997,National Institute of Allergy and Infectious Diseases,United States
U01AI037542,DESIGN AND IMMUNE MECHANISMS OF P FALCIPARUM CS VACCINE,0,1994,1997,National Institute of Allergy and Infectious Diseases,United States
U01AI036467,ANTIGENIZED ANTIBODY AND GENE IN MALARIA VACCINE,0,1994,1997,National Institute of Allergy and Infectious Diseases,United States
U01AI035365,LIVE ATTENUATED MULTIPLY DELETED HIV1 VACCINE FOR AIDS,0,1994,1998,National Institute of Allergy and Infectious Diseases,United States
U01AI026507,COMBINED VACCINE STRATEGIES FOR THE PREVENTION OF AIDS,0,1989,1998,National Institute of Allergy and Infectious Diseases,United States
U01AI026503,NOVEL IMDEF VIRUS VACCINES IN NHP MODELS,0,1988,1998,National Institute of Allergy and Infectious Diseases,United States
R56AI063396,Development of multi-antigen subunit SARS vaccines,284375,2006,2008,National Institute of Allergy and Infectious Diseases,United States
R55AI040302,STRUCTURAL AND CONFORMATIONAL ASPECTS IN PEPTIDE VACCINE,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R55AI039427,RECOMBINANT L MONOCYTOGENES AS AN SIV VACCINE,0,1996,1996,National Institute of Allergy and Infectious Diseases,United States
R44AI033301,CELL CULTURE PRODUCTION OF T GONDII T 263 VACCINE,0,1992,1997,National Institute of Allergy and Infectious Diseases,United States
R44AI032847,VACCINE TO TREAT HEPATITIS B VIRUS INFECTION,0,1992,1997,National Institute of Allergy and Infectious Diseases,United States
R44AI026028,ATTENUATION OF THE NYCBH VACCINE STRAIN OF VACCINIA,0,1988,1993,National Institute of Allergy and Infectious Diseases,United States
R43DK050890,ADHESIN BASED VACCINE TO PREVENT URINARY TRACT INFECTION,0,1996,1996,National Institute of Diabetes and Digestive and Kidney Diseases,United States
R43CA074665,DEVELOPMENT OF TUMOR VACCINES USING GPI LINKED MOLECULES,0,1997,1999,National Cancer Institute,United States
R43CA069885,THERAPEUTIC TUMOR VACCINE AGAINST HER 2/NEU,0,1996,1996,National Cancer Institute,United States
R43AI054075,Allergy Protection by Active IgE B Cell Vaccines,552946,2003,2004,National Institute of Allergy and Infectious Diseases,United States
R43AI046212,EPITOPE-DRIVEN HIV VACCINE TARGETING DENDRITIC CELLS,0,1999,2000,National Institute of Allergy and Infectious Diseases,United States
R43AI044532,ORAL DELIVERY OF ENCAPSULATED MULTIMERIC AIDS VACCINES,0,1999,2001,National Institute of Allergy and Infectious Diseases,United States
R43AI040397,DEVELOPMENT OF A VACCINE FOR CLOSTRIDIUM DIFFICILE,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI039906,UBIQUITIN FUSION FOR PEPTIDE IMMUNE DISPLAY AND VACCINES,0,1996,1996,National Institute of Allergy and Infectious Diseases,United States
R43AI039865,LYME VACCINE BASED ON BORRELIA DECORIN ADHESIN,0,1996,1996,National Institute of Allergy and Infectious Diseases,United States
R43AI039334,PEPTIDE ANTIIGE VACCINE FOR IMMUNOTHERAPY OF ALLERGY,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI039318,LYME VACCINE BASED ON BORRELIA TRANSFERIN RECEPTORS,0,1996,1996,National Institute of Allergy and Infectious Diseases,United States
R43AI039276,ORAL HIV-1 VACCINE TECHNOLOGIES USING OPTIVAX COPOLYMER,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI038081,PEPTIDE BASED VACCINE FOR PRIMATE MODEL OF AIDS,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI036003,"ORAL, LIVE, ATTENUATED VIBRIO VECTORED SSONNEI VACCINE",0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R43AI026028,ATTENUATION OF THE NYCBH VACCINE STRAIN OF VACCINIA,0,1988,1988,National Institute of Allergy and Infectious Diseases,United States
R29AI027332,CS PROTEIN T-EPITOPE POLYMORPHISM--MALARIA VACCINE,0,1988,1989,National Institute of Allergy and Infectious Diseases,United States
R21DK057206,A TARGETED PLANT-BASED VACCINE FOR TYPE I DIABETES,163941,1999,2002,National Institute of Diabetes and Digestive and Kidney Diseases,United States
R21DK057113,APC-TARGETING VACCINE FOR PREVENTION OF TYPE I DIABETES,164000,1999,2002,National Institute of Diabetes and Digestive and Kidney Diseases,United States
R21AI046329,DEVELOPMENT/EVALUATION OF HYBRID NOVEL MUCOSAL VACCINES,150000,1999,2002,National Institute of Allergy and Infectious Diseases,United States
R21AI046184,NEW STRATEGIES FOR BACTERIAL DELIVERY OF DNA VACCINES,237750,1999,2002,National Institute of Allergy and Infectious Diseases,United States
R21AI045396,HIV VACCINE STRATEGIES BASED ON A GOAT LENTIVIRUS--CAEV,368846,1999,2005,National Institute of Allergy and Infectious Diseases,United States
R21AI044369,DEVELOPMENT OF ENHANCED HIV 1 PSEUDOVIRION VACCINES,181850,1999,2002,National Institute of Allergy and Infectious Diseases,United States
R21AI040261,DEVELOPMENT OF AN ORAL MULTIVALENT SHIGELLA/ETEC VACCINE,0,1996,1997,National Institute of Allergy and Infectious Diseases,United States
R21AI040090,DEVELOPMENT OF A GENETIC VACCINE FOR M TUBERCULOSIS,0,1996,1998,National Institute of Allergy and Infectious Diseases,United States
R21AI038979,DETOXIFIED BACTERIAL TOXINS AS CTL VACCINE MOLECULES,0,1997,1999,National Institute of Allergy and Infectious Diseases,United States
R15AI037777,MUCOSAL VACCINES--HEAT LABILE TOXIN/ANTIGEN FUSIONS,0,1995,1997,National Institute of Allergy and Infectious Diseases,United States
R13CA067131,INTERNATIONAL CONFERENCE ON VACCINES FOR CANCER AND AIDS,0,1995,1996,National Cancer Institute,United States
R03OH003255,HEPATITIS B VACCINE ACCEPTANCE BY NURSING HOME WORKERS,0,1995,1997,Centers for Disease Control and Prevention,United States
R03AI058222,DNA/MVA HIV Vaccine for India,100000,2003,2005,National Institute of Allergy and Infectious Diseases,United States
R03AI045084,MUCOSAL IMMUNITY TO VIRULENT AND VACCINE-STRAIN CMV,142814,1999,2003,National Institute of Allergy and Infectious Diseases,United States
R03AI033668,EVALUATION OF ARI ORGANISMS FOR VACCINE DEVELOPMENT,0,1992,1995,National Institute of Allergy and Infectious Diseases,United States
R01RR008552,DEVELOPMENT OF SUBUNIT VACCINE FOR M PULMONIS IN MICE,0,1993,1997,National Center for Advancing Translational Sciences,United States
R01FD002545,DC TUMOR CONJUGATE VACCINE FOR IMMUNOTHERAPY,0,2005,2007,United States Food and Drug Administration,United States
R01AI044592,EVALUATION STUDIES--DNA VACCINE EXPRESSING SIVSM VLP,1010353,1999,2003,National Institute of Allergy and Infectious Diseases,United States
R01AI037166,DNA VACCINES-RESPONSES TO VECTORS WITH RABIES ANTIGENS,1273968,1994,2006,National Institute of Allergy and Infectious Diseases,United States
R01AI035196,DEVELOPMENT OF A POX-VECTORED MEASLES VACCINE,0,1993,1998,National Institute of Allergy and Infectious Diseases,United States
R01AI035137,MEASLES &MEASLES VACCINES--MECHANISMS OF IMMUNE INJURY,0,1993,1997,National Institute of Allergy and Infectious Diseases,United States
R01AI031224,GENE EXPRESSION FOR S MANSONI VACCINE ANTIGEN,0,1991,1997,National Institute of Allergy and Infectious Diseases,United States
R01AI021024,PREVENTION OF NEONATAL BACTEREMIA WITH PILUS VACCINE,0,1984,1987,National Institute of Allergy and Infectious Diseases,United States
P01AI056356,HSV-1 Amplicon Vectors for HIV Vaccine Delivery,11606890,2003,2009,National Institute of Allergy and Infectious Diseases,United States
P01AI052816,"HIV, TB, and Malaria Vaccine Development for Africa",14490691,2003,2009,National Institute of Allergy and Infectious Diseases,United States
P01AI024009,HSV VACCINE DESIGN--ABLATION OF VIRULENCE AND LATENCY,0,1987,1997,National Institute of Allergy and Infectious Diseases,United States
N43AI052598,DNA TECHNIQUES FOR PRODUCTION OF A VACCINE TO AIDS,0,1985,1986,National Institute of Allergy and Infectious Diseases,United States
N01HD953226,EVALUATE SAFETY OF VACCINES TO PREVENT SHIGELLOSIS-275953226,0,2004,2004,National Institute of Child Health and Human Development,United States
N01HD073269,CONJUGATE VACCINES DESIGNED TO PREVENT TYPHOID FEVER-275973269,217249,1997,2000,National Institute of Child Health and Human Development,United States
N01HD073264,KILLED ORAL CHOLERA VACCINE EFFECTIVENESS TRIAL--VIETNAM-275973264,0,1996,2001,National Institute of Child Health and Human Development,United States
N01HD072923,TEST OF ACELLULAR PERTUSSIS VACCINE IN INFANTS,0,1987,1988,National Institute of Child Health and Human Development,United States
N01HD053225,EVALUATION OF TYPHOID FEVER VI CONJUGATE VACCINE,0,1995,1997,National Institute of Child Health and Human Development,United States
N01HD033187,U.S. CLINICAL TRIAL OF ACELLULAR PERTUSSIS VACCINE,0,1993,1995,National Institute of Child Health and Human Development,United States
N01HD033186,U.S. CLINICAL TRIAL OF ACELLULAR PERTUSSIS VACCINE,0,1993,1995,National Institute of Child Health and Human Development,United States
N01HD023151,PRODUCTION OF NICHD DPT VACCINE FOR U.S. CLINICAL TRIALS,0,1992,1993,National Institute of Child Health and Human Development,United States
N01AO035154,OPERATION OF &EXPERIMENTAL VIRUS VACCINE PRODUCTION LAB,0,1992,1997,National Institute of Allergy and Infectious Diseases,United States
N01AI095041,ADVERSE CONSEQUENCES OF PERTUSSIS AND RUBELLA VACCINES,0,1989,1991,National Institute of Allergy and Infectious Diseases,United States
N01AI085343,PRIMATE IMMUNOLOGY LABORATORY FOR AIDS VACCINE R&D,411574,1998,2003,National Institute of Allergy and Infectious Diseases,United States
N01AI085342,Evaluation of Vaccines and Therapies in Adults/Elderly-26685342,0,1998,2003,National Institute of Allergy and Infectious Diseases,United States
N01AI085341,LAB SUP. FOR AIDS VACCINE &OTHER PREVENT. CLINICAL TRIA,750000,1998,2005,National Institute of Allergy and Infectious Diseases,United States
N01AI085340,PHASE II PNEUMOCOCCAL CONJUGATE VACCINE STUDY IN THE GAM,0,1998,2000,National Institute of Allergy and Infectious Diseases,United States
N01AI075320,TB Research Materials and Vaccine testing-26675320,979767,1997,2004,National Institute of Allergy and Infectious Diseases,United States
N01AI062553,STUDY OF MALARIA VACCINES IN HUMAN VOLUNTEERS,0,1986,1992,National Institute of Allergy and Infectious Diseases,United States
N01AI062528,FACILITY FOR STUDY OF INFECTIOUS DISEASE AND VACCINES,0,1985,1992,National Institute of Allergy and Infectious Diseases,United States
N01AI055263,MAO/EVALUATION OF AIDS VACCINES IN NONHUMAN PRIMATE,0,1995,1998,National Institute of Allergy and Infectious Diseases,United States
N01AI055260,EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE MODELS,0,1995,1999,National Institute of Allergy and Infectious Diseases,United States
N01AI052630,EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE MODELS,0,1995,1997,National Institute of Allergy and Infectious Diseases,United States
N01AI045237,VACCINE DEVELOPMENT--ESTABLISHMENT OF PRIORITIES FOR U S,0,1994,1999,National Institute of Allergy and Infectious Diseases,United States
N01AI045218,CORRELATE IMMUNE PROTECTION IN AIDS VACCINE RECIPIENTS,0,1994,1997,National Institute of Allergy and Infectious Diseases,United States
N01AI045202,CENTRAL LAB FOR AIDS/HIV VACCINE EFFICACY TRIALS,0,1994,2000,National Institute of Allergy and Infectious Diseases,United States
N01AI040072,Production and Testing of a MVA Vaccine-266040072,0,2005,2005,National Institute of Allergy and Infectious Diseases,United States
N01AI040069,Population Genetics Analysis Program: Immunity to Vaccines/Infections--266040069,0,2005,2006,National Institute of Allergy and Infectious Diseases,United States
N01AI040068,POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION-266040068,0,2006,2006,National Institute of Allergy and Infectious Diseases,United States
N01AI040067,POPULATION GENETICS ANALYSIS PROGRAM:  IMMUNITY TO VACCINES/INFECTIONS-266040067,0,2006,2006,National Institute of Allergy and Infectious Diseases,United States
N01AI040064,POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION-266040064,0,2006,2006,National Institute of Allergy and Infectious Diseases,United States
N01AI032512,HAEMOPHILUS INFLUENZA TYPE B VACCINE IN HIGH RISK INFANT,0,1983,1986,National Institute of Allergy and Infectious Diseases,United States
N01AI030042,HIV Vaccine Design and Development Teams /HVDDT/-26630042,0,2003,2004,National Institute of Allergy and Infectious Diseases,United States
N01AI030030,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS (HVDDT)-266030030,0,2003,2003,National Institute of Allergy and Infectious Diseases,United States
N01AI030029,HIV Vaccine Design and Development Teams /HVDDT/-26630029,0,2004,2004,National Institute of Allergy and Infectious Diseases,United States
N01AI025494,DEVELOPMENT AND TESTING OF VACCINES AGAINST ANTHRAX-266025494,0,2002,2004,National Institute of Allergy and Infectious Diseases,United States
N01AI025492,Development and Testing of Vaccines Against Anthrax-266025492,0,2002,2005,National Institute of Allergy and Infectious Diseases,United States
N01AI025458,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS-266025458,0,2003,2005,National Institute of Allergy and Infectious Diseases,United States
N01AI022678,STUDY ISSUES AND PRIORITIES FOR NEW VACCINE DEVELOPMENT,0,1982,1985,National Institute of Allergy and Infectious Diseases,United States
N01AI015124,EVAL OF VACCINE PROPH AGAINST INFECT DISEASES IN CHILDRN,0,1991,1996,National Institute of Allergy and Infectious Diseases,United States
N01AI015106,CENTRAL LAB FOR AIDS VACCINE CLINICAL TRIALS,0,1991,1996,National Institute of Allergy and Infectious Diseases,United States
N01AI015094,EVALUATION IN MONKEYS OF VACCINES FOR SAIDS,0,1990,1996,National Institute of Allergy and Infectious Diseases,United States
N01AI012674,DEVELOP AN H INFLUENZAE TYPE B VACCINE,0,1981,1985,National Institute of Allergy and Infectious Diseases,United States
N01AI012666,"FACILITY FOR STUDY OF INFECTIOUS DISEASES, VACCINES",0,1980,1985,National Institute of Allergy and Infectious Diseases,United States
N01AI005397,HIV Vaccine Design and Development Teams-26605397,3773578,2000,2005,National Institute of Allergy and Infectious Diseases,United States
N01AI005396,HIV Vaccine Design and Development Teams-26605396,7545418,2000,2005,National Institute of Allergy and Infectious Diseases,United States
N01AI005395,HIV Vaccine Design and Development Teams-26605395,3213894,2000,2005,National Institute of Allergy and Infectious Diseases,United States
N01AI005394,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS-266005394,2527964,2000,2005,National Institute of Allergy and Infectious Diseases,United States
N01AI005053,DEVELOP LIVE ATTENTUATED COLD ADAPTED INFLUENZA VACCINE,0,1989,1993,National Institute of Allergy and Infectious Diseases,United States
N01AI002645,TEST RESPIRATORY VIRUS AND BACTERIAL VACCINES IN INFANTS,0,1980,1985,National Institute of Allergy and Infectious Diseases,United States
N01AI000068,POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION-266000068,0,2004,2005,National Institute of Allergy and Infectious Diseases,United States
N01AI000067,POPULATION GENETICS ANALYSIS PROGRAM:  IMMUNITY TO VACCINES/INFECTIONS-266000067,0,2004,2005,National Institute of Allergy and Infectious Diseases,United States
N01AI000065,POPULATION GENETICS ANALYSIS PROGRAM: IMMUNITY TO VACCINES/INFECTIONS--266000065,0,2004,2006,National Institute of Allergy and Infectious Diseases,United States
N01AI000064,POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION-266000064,0,2004,2005,National Institute of Allergy and Infectious Diseases,United States
K11AI001061,IMMUNE INTERACTIONS OF GONORRHEA AND VACCINE DEVELOPMENT,0,1991,1996,National Institute of Allergy and Infectious Diseases,United States
K08AG000548,"ANTIBODY DIVERSITY, AGE AND INFLUENZA VACCINE EFFICACY",0,1992,1998,National Institute on Aging,United States
K01OH000131,HEALTH CARE WORKER COMPLIANCE WITH HEPATITIS B VACCINE,0,1993,1997,Centers for Disease Control and Prevention,United States
H23IP000767,PREVENTING AND MITIGATING VACCINE PREVENTABLE DISEASE THROUGH IMMUNIZATION,12239874,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000765,TO PREVENT VACCINE-PREVENTABLE DISEASE THROUGH MAINTAINING IMMUNIZATION STRUCTURE,24666320,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000762,Immunization Grant and Vaccines for Children's Program,23776040,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000756,NEBRASKA IMMUNIZATION AND VACCINES FOR CHILDREN PROGRAM,6919041,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000746,GUAM IMMUNIZATION AND VACCINES FOR CHILDREN PROGRAMS,3954801,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000744,GEORGIA IMMUNIZATIONS AND VACCINES FOR CHILDREN GRANTS,26897364,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000742,FSM IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,3732639,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000731,PREVENTION & CONTROL OF COMMUNICABLE AND VACCINE PREVENTABLE DISEASES,10030916,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000725,KY IMMUNIZATION PROGRAM IMMUNIZATION & VACCINE FOR CHILDREN PROGRAM,13007636,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000721,HAWAII IMMUNIZATION AND VACCINES FOR CHILDREN PROGRAM,9628383,2013,2017,Centers for Disease Control and Prevention,United States
H23IP000708,Building Capacity for Immunization Billing and Vaccine Barcode Reading,835028,2012,2015,Centers for Disease Control and Prevention,United States
F33AI008851,NEISSERIA MENINGITIDIS GROUP B;IDIOTYPES AND VACCINES,0,1993,1993,National Institute of Allergy and Infectious Diseases,United States
F32DK009360,ATTENUATED SHIGELLA AS TOXIGENIC E COLI VACCINE,0,1996,1996,National Institute of Diabetes and Digestive and Kidney Diseases,United States
F32AI009773,VACCINE POTENTIAL OF PAR PROTEINS OF TRYPANOSOMA CRUZI,0,1997,1999,National Institute of Allergy and Infectious Diseases,United States
F32AI008991,LIVE AND ATTENUATED VIBRIO CHOLERAE VACCINE STRAINS,0,1994,1995,National Institute of Allergy and Infectious Diseases,United States
F32AI008965,DEVELOPMENT OF A SINGLE DOSE TETANUS VACCINE,0,1994,1994,National Institute of Allergy and Infectious Diseases,United States
F31AI010487,SALMONELLA AS A VACCINE TOOL AGAINST HIV,113650,2000,2002,National Institute of Allergy and Infectious Diseases,United States
F05TW004386,FACTORS INFLUENCING HIB DISEASE AND VACCINE EFFICACY,0,1990,1991,Fogarty International Center,United States
F05TW003315,DEVELOPMENT OF VACCINE AGAINST GROUP B STREPTOCOCCI,0,1985,1985,Fogarty International Center,United States
272200800057C-1-0-2,Vaccine and Treatment Evaluation Units,2723435,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800057C-1-0-1,Vaccine and Treatment Evaluation Units,371377,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800056C-0-0-1,Advanced Development of Multivalent Filovirus Vaccines,13496364,2008,2013,National Institute of Allergy and Infectious Diseases,United States
272200800051C-0-0-1,Development of an Anthrax Vaccine,13072863,2008,2011,National Institute of Allergy and Infectious Diseases,United States
272200800008C-2-0-2,Vaccine and Treatment Evaluation Units,2809421,2008,2008,National Institute of Allergy and Infectious Diseases,United States
272200800008C-2-0-1,Vaccine and Treatment Evaluation Units,383103,2008,2008,National Institute of Allergy and Infectious Diseases,United States
272200800007C-1-0-2,Vaccine and Treatment Evaluation Units,2729831,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800007C-1-0-1,Vaccine and Treatment Evaluation Units,372250,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800006C-2-0-2,Vaccine and Treatment Evaluation Units,2628793,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800006C-2-0-1,Vaccine and Treatment Evaluation Units,358447,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800005C-1-0-2,Vaccine and Treatment Evaluation Units,2746553,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800005C-1-0-1,Vaccine and Treatment Evaluation Units,374527,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800004C-1-0-2,Vaccine and Treatment Evaluation Units,2634897,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800004C-1-0-1,Vaccine and Treatment Evaluation Units,359304,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800003C-2-0-1,Vaccine and Treatment Evaluation Units,337232,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800002C-1-0-2,Vaccine and Treatment Evaluation Units,2758811,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200800002C-1-0-1,Vaccine and Treatment Evaluation Unit,376202,2007,2014,National Institute of Allergy and Infectious Diseases,United States
272200700056C-0-0-1,Global HIV AIDS Vaccine Enterprise Secretariat,1735409,2007,2009,National Institute of Allergy and Infectious Diseases,United States
272200700056C-0-0-0,GLOBAL HIV VACCINE ENTERPRISE,1735409,2007,2009,National Institute of Allergy and Infectious Diseases,United States
7262-08,Translational Development of Novel Vaccine Therapies,6250000,2007,2012,Leukemia and Lymphoma Society,United States
09PH-008-961-2596,Rotavirus vaccine and prevention of hospitalization,20000,2010,2011,Gerber Foundation,United States
0319223B/3,Verbundprojekt: EUREKA-Projekt: Malaria-Impfstoff (EU 101) - Teilvorhaben: Gentechnologische Entwicklung einer Malaria-Vakzine - Phase 2,2247441,1988,1991,Federal Ministry of Education and Research,Germany
01KA1304,"'EDCTP-Malaria Impfstoff: Biometrie und Parasiten-Quantifizierung zur Entwicklung neuer malariaimpfstoffe, -medikamente und -miagnostika in Afrika.'",79683,2013,2014,Federal Ministry of Education and Research,Germany
01KA0802,"EDCTP-HIV-Vakzine I: Durchführung eine Phase IB HIV Impfstoffstudie (DNA / NYVAC) in Mbeya, Tansania.",211751,2008,2012,Federal Ministry of Education and Research,Germany
N/A,Investigation of Novel Vaccine Strategies for Influenza: Targeting Innate and Adaptive Immunity for Cross-protective Vaccines,1102716,2008,2011,Canadian Institutes of Health Research,Canada
2015R1C1A1A02037060,일반백신 또는 긴급백신제제의 뇌구조 및 기능에 대한 안전성 신속검정,0,2015,2016,National Research Foundation of Korea,South Korea
2013R1A1A2061340,비만 마우스에서의 호흡기 바이러스에 대한 백신의 효능 측정 및 비만 개선을 통한 백신 역량 강화 평가,0,2013,2014,National Research Foundation of Korea,South Korea
2010-00240,마우스 모델에서 모체의 결핵 감염이 신생아의 결핵 백신 효과에 미치는 영향 및 신규 결핵 백신 효능 검증,0,2010,2011,National Research Foundation of Korea,South Korea
194341,Development of vaccine strategies for measles and malaria using oral bacterial vectors and edible plant vaccines,46858,2002,2005,National Health and Medical Research Council,Australia
OPP51764,To test a new bacterial synthesis method to produce glycoconjugate vaccines to generate an improved vaccine against pneumococcal disease.,100000,2008,2009,Bill & Melinda Gates Foundation,United States
OPP1036030,To produce more poliovirus vaccine supply by silencing non-essential virus resistance genes to develop enhanced vaccine cell lines.,99632,2011,2012,Bill & Melinda Gates Foundation,United States
OPP41427,To support the AIDS Vaccine 2006 conference which will bring together scientists in the field of HIV vaccine research.,357500,2006,2007,Bill & Melinda Gates Foundation,United States
OPP1060868,To develop and field test a durable liner for vaccine carriers to protect vaccines from freezing.,98231,2012,2013,Bill & Melinda Gates Foundation,United States
OPP1033096,To develop an envelope vaccine antigen that allows immune recognition and is an effective vaccine antigen,896490,2011,2015,Bill & Melinda Gates Foundation,United States
272201600039C-0-0-1,DEVELOPMENT OF A NOVEL SALMONELLA PARATYPHI A VACCINE,449620,2016,2018,National Institute of Allergy and Infectious Diseases,United States
9671687,ヒト精子抗原を用いた経口ワクチン及び遺伝子ワクチンの開発に関する生殖免疫学的研究,4956,1997,1997,Japan Society for the Promotion of Science,Japan
hrc_04bb2ea4,RV3 Rotavirus Vaccine: A Phase II clinical trial for a human neonatal rotavirus vaccine for the global community,322481,2009,2011,Health Research Council of New Zealand,New Zealand
N01AI30023-14-0-1,Development of a Coronavirus Vaccine,1000,2003,2012,National Institute of Allergy and Infectious Diseases,United States
BW-08028,Insights into CD4+ T cell responses against cancer vaccines from analysis of responses to a conventional vaccine,0,2008,2014,Bloodwise,United Kingdom
09/16282-0,Adjuvant properties of cellular vaccines: combination of cellular pertussis vaccine and BCG with Streptococcus pneumoniae antigens,0,2010,2012,São Paulo Research Foundation,Brazil
00/PI.1/B045,Pathogen-derived immunomodulatory molecules: future immunotherapeutics and vaccines,9265633,2001,2006,Science Foundation Ireland,Ireland
06/RFP/GEN028,Can plant plastids produce a candidate flu vaccine,327096,2006,2009,Science Foundation Ireland,Ireland
62863,Information dissemination on the human papillomavirus vaccine,16141,2008,2009,Social Sciences and Humanities Research Council,Canada
N01AI30023-13-0-1,Development of a Coronavirus Vaccine,25831,2003,2012,National Institute of Allergy and Infectious Diseases,United States
272201200003I-1-27200008-1,Task X8: Efficacy Testing of Ebola Virus Vaccines,1644104,2013,2016,National Institute of Allergy and Infectious Diseases,United States
72624,USE OF THE VACCINE ADJUVANT FOR IMMUNOMODULATION OF THE INFECTION CAUSED BY TRYPANOSOMA BRUCEI: AN APPROACH TO VACCINE DESIGN,152343,2007,2010,Foundation for Science and Technology,Portugal
111077,Development of DNA-based vaccines for bovine viral diarrhoea virus. Développement des vaccins à base d'ADN le virus de diarrhée bovine.,170773,1996,1998,Natural Sciences and Engineering Research Council,Canada
N01AI052575,TESTING VACCINES IN CHILDREN,0,1985,1990,National Institute of Allergy and Infectious Diseases,United States
71998,Frameshifts as a Cancer Vaccine,1200000,2007,2010,W. M. Keck Foundation,United States
N01AI065314,SIMIAN VACCINE EVALUATION UNITS,2560239,1996,2001,National Institute of Allergy and Infectious Diseases,United States
30200246,HPV双启动子DNA疫苗和重组腺病毒疫苗的联合应用研究,23024,2003,2005,National Natural Science Foundation of China,China
5395449580,Vaccines against helminth infections (acronym PARAVAC),0,2011,2015,Belgian Federal Science Policy Office,Belgium
25830115,The mechanisms of macrophage dependent vaccine,39940,2013,2015,Japan Society for the Promotion of Science,Japan
Z01AI000416,Recombinant Vaccines for Prevention of AIDS and Other Diseases,3320228,1985,2008,National Institute of Allergy and Infectious Diseases,United States
50343004,SARS疫苗高分子载体的模拟研究,12078,2003,2004,National Natural Science Foundation of China,China
1031473,Characterisation of rotavirus vaccine escape - potential for significant impact on vaccination program,514201,2012,2014,National Health and Medical Research Council,Australia
185875,Conference: Genetic vaccines - benefits and challenges,33782,2007,2009,The Research Council of Norway,Norway
10-04-09827,Участие в GENE-BASED VACCINES - GBV2010 Conference,0,2010,2010,Russian Foundation for Basic Research,Russia
OPP1117200,To development of a new safer Oral Polio Vaccine against type 2 strain (nOPV2) with lower risk of circulating vaccine derived polio virus (cVDVP) or vaccine associated paralytic poliomyelitis (VAPP) than existing Sabin mOPV 2,3081165,2014,2018,Bill & Melinda Gates Foundation,United States
OPP1015149,"To test a new vaccine technology that modulates a host cytokine response to HIV vaccines. If successful, this technology may also enhance T-cell mediated immunity to other vaccine antigens, such as Tuberculosis.",100000,2010,2011,Bill & Melinda Gates Foundation,United States
OPP1068031,To produce new and more potent vaccines with increased stability by testing a vaccine platform based on protein crystals (MicroCubes) produced by insect viruses for developing a candidate vaccine against HIV.,428770,2013,2016,Bill & Melinda Gates Foundation,United States
OPP1045902,To develop better polio vaccines by researching whether adding immune pressure against proteins found in the attenuated strains of the oral polio vaccine leads to the emergence of recombinant circulating vaccine-derived polioviruses,100000,2011,2014,Bill & Melinda Gates Foundation,United States
OPP1025568,"To develop and test a vaccine combining a novel placental malaria vaccine candidate with the cervical cancer vaccine, with the potential of inducing a strong protective response against both diseases simultaneously",100000,2010,2012,Bill & Melinda Gates Foundation,United States
OPP1109210,"To bring together African researchers, vaccine implementers and public health academics to share information regarding rotavirus vaccines within Africa, and to exchange information and lessons regarding the impact of the vaccines",98212,2014,2014,Bill & Melinda Gates Foundation,United States
64571,"Sometimes it's take that hill, sometimes it's take that vaccine:  the Persian Gulf war and the anthrax vaccine controversy",16141,2008,2009,Social Sciences and Humanities Research Council,Canada
QLK4-CT-1999-50407,Training in vaccine research: vaccine against peptic ulcer,234957,2001,2005,European Commission,Belgium
N01AI50040-19-0-1,Tularemia Vaccine Development,336464,2005,2012,National Institute of Allergy and Infectious Diseases,United States
7190763100,Polymeric microparticulate vaccine formulations based on hydrogen bonding,0,2014,2017,Belgian Federal Science Policy Office,Belgium
26_4129,Production of a recombinant vaccine against human cytomegalovirus in plant cells,0,2014,2017,Belgian Federal Science Policy Office,Belgium
30_24854,GSK VACCINES - COURS INTRO MIN PME Convention -Course with Minor Entrepreneurschip,0,2015,2018,Belgian Federal Science Policy Office,Belgium
N/A,Vaccine Effectiveness: An integrated approach for monitoring influenza vaccine effectiveness to inform public health policy and influenza immunization program implementation,1790,2016,2017,Canadian Institutes of Health Research,Canada
N/A,Vaccine Effectiveness: An integrated approach for monitoring influenza vaccine effectiveness to inform public health policy and influenza immunization program implementation,1777,2016,2017,Canadian Institutes of Health Research,Canada
N/A,Vaccine Effectiveness: An integrated approach for monitoring influenza vaccine effectiveness to inform public health policy and influenza immunization program implementation,1159,2016,2017,Canadian Institutes of Health Research,Canada
N/A,Vaccine Effectiveness: An integrated approach for monitoring influenza vaccine effectiveness to inform public health policy and influenza immunization program implementation,2328,2016,2017,Canadian Institutes of Health Research,Canada
16IN0171,"Verbundprojekt: Integriertes, patientennahes Verfahren zur Herstellung einer therapeutischen zellulären Vakzine im geschlossenen System, Teilvorhaben: Genetisch modifizierte DC-Vakzine mit verbesserter Antigenpräsentation",142191,2003,2006,Federal Ministry for Economic Affairs and Energy,Germany
16IN0170,"Verbundprojekt: Integriertes, patientennahes Verfahren zur Herstellung einer therapeutischen zellulären Vakzine im geschlossenen System, Teilvorhaben: Geschlossenes, GMP-fähiges Verfahren für DC-Vakzine",654734,2003,2006,Federal Ministry for Economic Affairs and Energy,Germany
03 8689 /0,Verbundprojekt: Impfstoffentwicklung Gegen Herpesviren: Ein flexibles System zur gezielten Antigen-Variation bei Humanen Influenza-Viren für die Herstellung von Vakzinen,174044,1985,1988,Federal Ministry of Education and Research,Germany
0315281A,ERA Net EuroTransBio-2: Neue Technologie für erfolgreiche Impfstoffstrategien: Crossbeta Adjuvanz-Technologie am Beispiel von Protein-basierten Impfstoffen gegen Influenza H5N1 Viren,277036,2008,2010,Federal Ministry of Education and Research,Germany
01QE1522,"Verbundprojekt: Entwicklung eines low-cost intranasalen Vaccines mit universellem Schutz gegen Pneumococcus Infektionen, Teilprojekt: Sicherheits- und Wirksamkeitsuntersuchungen des Vaccines",69213,2015,2018,Federal Ministry of Education and Research,Germany
01KA0804,"EDCTP - Malariaimpfstoffe I: Förderung der immunologischen und der klinischen Forschungs-Kompetenz im Rahmen multizentrischer, internationaler klinischer Studien an Malariavakzinen der Phasen I bis IIb",1443557,2008,2013,Federal Ministry of Education and Research,Germany
01KA0801,EDCTP-HIV-Vakzine I: Bestimmung der zellulären Immunantwort nach Impfung mit einer DNA / MVA HIV Vakzine bei 70 Freiwilligen.,541177,2008,2012,Federal Ministry of Education and Research,Germany
01GU0709,Verbundprojekt: Innovative bakterielle Tumorimpfstoffe - Teilprojekt 2/3: Entwicklung eines oralen rekombinanten Salmonellenvakzins der zweiten Generation für die Tumortherapie,873846,2008,2011,Federal Ministry of Education and Research,Germany
N/A,"Best Brains Exchange: 'Achievement of Optimal Vaccine Coverage Rates in Canada: Identifying and Addressing the Problem of Vaccine Hesitancy', February 3, 2015, Ottawa.",932,2014,2015,Canadian Institutes of Health Research,Canada